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Mini-combined test compared with NICE guidelines for
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Liona C Poon ,1 David Wright ,2 Steve Thornton ,3 Ranjit Akolekar ,4
Peter Brocklehurst 5 and Kypros H Nicolaides 1*
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London, UK
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*Corresponding author kypros@fetalmedicine.com
Background: The traditional method of risk assessment for pre-eclampsia recommended by the
National Institute for Health and Care Excellence is based on maternal factors and it recommends that
high-risk women should be treated with aspirin. An alternative method of screening is based on the
competing risk model, which uses Bayes’ theorem to combine maternal factors with mean arterial
pressure, the uterine artery pulsatility index, serum placental growth factor and pregnancy-associated
plasma protein-A at 11–13 weeks’ gestation.
Objective: The primary aim was to compare the performance of screening by risks obtained using
the competing risk model with risk assessment using the National Institute for Health and Care
Excellence guidelines.
Design: This was a prospective multicentre observational study.
Setting: The setting was seven NHS maternity hospitals in England.
Participants: Participants were women with singleton pregnancy attending for a routine hospital visit
at 11+0–13+6 weeks’ gestation between April and December 2016.
Main outcome measures: The performance of screening for pre-eclampsia by the competing risk
model was compared with the National Institute for Health and Care Excellence method. Relative
reductions in risk with aspirin prophylaxis of 30% and 60% were assumed for all pre-eclampsia and
preterm pre-eclampsia, respectively. The primary comparison was the detection rate of the National
Institute for Health and Care Excellence method with the detection rate of a mini-combined test
(including maternal factors, mean arterial pressure and pregnancy-associated plasma protein-A) in the
prediction of all pre-eclampsia for the same screen-positive rate determined by the National Institute
for Health and Care Excellence method.
Results: In 473 (2.8%) of the 16,747 pregnancies there was development of pre-eclampsia, including
142 (0.8%) women with preterm pre-eclampsia. The screen-positive rate by the National Institute for
Health and Care Excellence method was 10.3%. For all pre-eclampsia, the false-positive and detection
rates by the National Institute for Health and Care Excellence method were 9.7% and 31.6%, respectively.
For preterm pre-eclampsia, the false-positive and detection rates were 10.0% and 42.8%, respectively.
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Compliance with the National Institute for Health and Care Excellence recommendation that high-risk
women should be treated with aspirin from the first trimester was 23%. For the same screen-positive
rate, the detection rate of the mini-combined test for all pre-eclampsia was 42.8%, which was superior
to that of the National Institute for Health and Care Excellence method by 11.2% (95% confidence
interval 6.9% to 15.6%). The increase in detection for the same screen-positive rate was accompanied
by a reduction in false-positive rate of 0.3%. For the same screen-positive rate as National Institute
for Health and Care Excellence, the detection rate for preterm pre-eclampsia by combining maternal
factors, mean arterial pressure and placental growth factor was 67.3% compared with 44.1% with the
National Institute for Health and Care Excellence method. With the addition of the uterine artery
pulsatility index, the detection rate was 78.6%. This was higher than that of the National Institute for
Health and Care Excellence method by 35.5% (95% confidence interval 25.2% to 45.8%). Calibration of
risks for pre-eclampsia was generally good, with the calibration slope very close to 1.0. The feasibility
of incorporating a new biomarker was demonstrated. However, the addition of inhibin A to the full
combined test did not improve the detection rates for all pre-eclampsia and preterm pre-eclampsia
(61% and 80%, respectively). The same screening model for preterm pre-eclampsia by a combination
of maternal factors, mean arterial pressure, the uterine artery pulsatility index and placental growth
factor achieved detection rates of 45.8% and 56.3%, respectively, for preterm small for gestational age
and early small for gestational age neonates.
Limitation: The study did not include a health economic assessment.
Conclusion: The findings suggest that performance of screening for pre-eclampsia provided by a
combination of maternal factors and biomarkers is superior to that achieved by current National
Institute for Health and Care Excellence guidelines.
Future work: Future work is required to identify potential biomarkers for further improvement of the
competing risk model and to carry out a health economic assessment.
Trial registration: Current Controlled Trials ISRCTN83611527.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership. This will be published
in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 8. See the NIHR Journals Library website for
further project information.
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Pre-eclampsia is a medical condition characterised by high blood pressure and the presence ofprotein in the urine of a pregnant woman. There could also be impaired function in organs such as
the liver, kidneys and brain. It occurs in 2–3% of all pregnancies. The effects of pre-eclampsia can be
serious for both the mother and the baby, especially when the disease is severe and requires delivery
of the baby before 37 weeks’ gestation (i.e. preterm pre-eclampsia).
There is evidence that in high-risk women their risk for preterm pre-eclampsia can be reduced
substantially by taking low-dose aspirin (i.e. 150 mg) every day from the 12th to the 36th week of
pregnancy. There is a need for accurate prediction of preterm pre-eclampsia in early pregnancy.
The National Institute for Health and Care Excellence has issued guidelines recommending that the
way to determine whether or not a woman is at high risk for developing pre-eclampsia depends on her
characteristics and medical history. Alternatively, we have developed a new method of screening that
combines the information from maternal characteristics and medical history with the results from
measurements of blood pressure, blood flow that supplies the uterus and levels of two placental
proteins in the mother’s blood to calculate the individual risk for developing preterm pre-eclampsia.
In this study of 16,747 women, 473 (2.8%) developed pre-eclampsia, including 142 (0.8%) women with
preterm pre-eclampsia. The proportion of women considered as high risk by the National Institute for
Health and Care Excellence method was ≈ 10%. The proportions of all pre-eclampsia and preterm
pre-eclampsia cases with a high-risk result were 32% and 43%, respectively. We found that only 23%
of high-risk women identified by the National Institute for Health and Care Excellence method actually
received aspirin. The proportion of preterm pre-eclampsia cases with a high-risk result based on the
combined test was 67%, which was much higher than that of the National Institute for Health and
Care Excellence method (i.e. 44%). We conclude that our method of screening by a combination of
maternal factors and various tests is superior to that achieved by current National Institute for Health
and Care Excellence guidelines.
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Pre-eclampsia, which affects 2–3% of pregnancies, is a major cause of maternal and perinatal morbidity
and mortality. Pre-eclampsia can be subdivided into preterm pre-eclampsia, with delivery before 37 weeks’
gestation, and term pre-eclampsia. Preterm pre-eclampsia is associated with a higher incidence of adverse
short- and long-term outcomes. Recent evidence suggests that the risk of preterm pre-eclampsia can be
substantially reduced by use of aspirin, given from 11–14 to 36 weeks’ gestation in high-risk women.
Identification of the high-risk group is based on maternal characteristics and medical history, as defined
by the National Institute for Health and Care Excellence guidelines, but the performance of such an
approach and the uptake of aspirin have not been evaluated by prospective studies. An alternative
approach to screening for pre-eclampsia, which allows estimation of individual patient-specific risks of
pre-eclampsia requiring delivery before a specified gestation, is to use a survival time model for gestational
age at delivery with pre-eclampsia. Implementation using Bayes’ theorem allows an a priori distribution of
gestational age at delivery with pre-eclampsia, obtained from maternal characteristics and medical history,
to be combined with the results of various biophysical and biochemical measurements at different stages in
pregnancy (i.e. the competing risk model). Extensive research in the last decade has led to the identification
of four potentially useful biomarkers at 11–13 weeks’ gestation: (1) mean arterial pressure, (2) uterine
artery pulsatility index, (3) serum pregnancy-associated plasma protein-A and (4) serum placental
growth factor.
Objectives
The primary aim of the study was to compare the performance of first trimester screening for
pre-eclampsia by the competing risk model with that of the current National Institute for Health and
Care Excellence guidelines. The objectives were to:
1. finalise the algorithm used in the competing risk model
2. evaluate the performance of the new method compared with that recommended by the National
Institute for Health and Care Excellence
3. provide the predictive performance of the new method
4. explore the possibility of carrying out first-stage screening in the whole population by some of the
components of the complete test and reserving the rest for a subgroup of the population selected
on the basis of the risk derived from first-stage screening
5. explore the potential value of another biomarker, inhibin A, in predicting pre-eclampsia
6. examine the performance of the new method in the prediction of small for gestational age neonates.
Methods
This was a prospective multicentre observational study in seven NHS maternity hospitals in England,
between April and December 2016. Women aged > 18 years with a singleton pregnancy and a live fetus
at the 11- to 13-week scan were included in the study. Women who were unconscious or severely ill at
the time of recruitment, those with learning difficulties or serious mental illness and those with major
fetal abnormality identified at the 11- to 13-week scan were excluded from the study.
Participants who provided written informed consent had recordings of maternal characteristics, medical
history and measurements of mean arterial pressure, uterine artery pulsatility index, placental growth
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factor and pregnancy-associated plasma protein-A at 11–13 weeks’ gestation. The decision concerning
administration of aspirin was made by the attending clinicians in accordance with routine standard of
care at each site and the information was recorded in the research database both at the time of screening
and during collection of data on pregnancy outcome.
Pre-eclampsia was defined according to the criteria of the International Society for the Study of
Hypertension in Pregnancy or the American College of Obstetricians and Gynecologists. The performance
of screening for pre-eclampsia by the competing risk model was compared with that of the National
Institute for Health and Care Excellence method. Some patients received aspirin and in the comparison of
sensitivities appropriate adjustments were made. Primary comparison was detection rate of National
Institute for Health and Care Excellence method compared with a mini-combined test (including
maternal factors, mean arterial pressure and pregnancy-associated plasma protein-A) in the prediction
of all pre-eclampsia, for the same screen-positive rate determined by the National Institute for Health
and Care Excellence method using McNemar’s test. Key secondary comparisons were detection rate of
risk assessment recommended by the National Institute for Health and Care Excellence guidelines
compared with screening by the competing risk model with three combinations of markers [i.e. (1) maternal
factors, mean arterial pressure and pregnancy-associated plasma protein-A, (2) maternal factors,
mean arterial pressure and placental growth factor, and (3) maternal factors, mean arterial pressure,
uterine artery pulsatility index and placental growth factor or triple test] in the prediction of preterm
pre-eclampsia.
We proposed to recruit 16,850 women and on the assumption of a 5% no follow-up rate there would
be 16,000 women for evaluation. On the extreme assumption that 90% of the National Institute for
Health and Care Excellence screened-positive patients and 10% of the National Institute for Health
and Care Excellence screened-negative patients would be treated with aspirin and that aspirin reduces
the incidence of all pre-eclampsia by 50%, the power to detect a 10% difference in detection rate
between the National Institute for Health and Care Excellence method and the mini-combined test in
the prediction of all pre-eclampsia at the one-sided 2.5% level would be > 80%.
We performed the following additional studies. First, we examined the calibration. Second, we evaluated
a two-stage screening approach in the detection of preterm pre-eclampsia and early pre-eclampsia at an
overall screen-positive rate of 10% and 20%, respectively, from a policy in which first-stage screening
of the whole population is carried out by some of the components of the triple test and second-stage
screening is carried out by the full triple test on women selected on the basis of results from first-stage
screening. Third, we conducted a case–control study and a screening study to evaluate the potential
value of inhibin A in improving the performance of screening provided by the other biomarkers. Last,
we estimated the proportion of small for gestational age neonates born at ≥ 37, < 37 and < 32 weeks’
gestation with a first-trimester combined risk for preterm pre-eclampsia (calculated by the competing
risk model through the triple test) of > 1 in 100.
Results
Screening for pre-eclampsia was carried out in 17,051 women and outcome data were obtained from
16,747 women. Pre-eclampsia developed in 473 (2.8%) pregnancies, including 142 (0.8%) cases of
preterm pre-eclampsia. Aspirin was taken by 400 (23.2%) women in the National Institute for Health
and Care Excellence screen-positive group and 349 (2.3%) in the National Institute for Health and Care
Excellence screen-negative group. The screen-positive rate by the National Institute for Health and Care
Excellence method was 10.3% and the detection rate for all pre-eclampsia was 30.4% (95% confidence
interval 26.3% to 34.6%). In screening by the competing risk model using maternal factors, mean arterial
pressure and pregnancy-associated plasma protein-A, the detection rate of all pre-eclampsia was
42.5% (95% confidence interval 38.0% to 46.9%) and the difference in detection rate between the two
methods was 12.1% (95% confidence interval 7.9% to 16.2%). After adjustment for the effect of aspirin
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(i.e. a 30% reduction in rate of all pre-eclampsia) in those receiving this drug, the detection rate of the
National Institute for Health and Care Excellence method was 31.5% (95% confidence interval 27.3%
to 35.7%), that of the competing risk model was 42.8% (95% confidence interval 38.3% to 47.2%) and the
difference between the two methods was 11.3% (95% confidence interval 7.1% to 15.5%). The detection
rate of the National Institute for Health and Care Excellence method for preterm pre-eclampsia was 40.8%
(95% confidence interval 32.8% to 48.9%), which was lower than that of the competing risk model
using maternal factors, mean arterial pressure and pregnancy-associated plasma protein-A (53.5%,
95% confidence interval 45.3% to 61.7%), the competing risk model using maternal factors, mean arterial
pressure and placental growth factor (69.0%, 95% confidence interval 61.4% to 76.6%) and the competing
risk model using the triple test (82.4%, 95% confidence interval 76.1% to 88.7%). After adjustment for the
effect of aspirin (i.e. a 60% reduction in rate of preterm pre-eclampsia) in those receiving this drug, the
difference in detection rate of the three competing risk models from the National Institute for Health and
Care Excellence method were 10.5% (95% confidence interval 2.3% to 18.8%), 24.0% (95% confidence
interval 14.3% to 33.7%) and 35.1% (95% confidence interval 25.1% to 45.0%), respectively.
Calibration of risks for the incidence of pre-eclampsia was good and the calibration slope was very
close to 1.0. In the two-stage screening a similar screen-positive rate and detection rate was achieved
at substantially lower costs than with carrying out screening with all biomarkers in the whole population.
If the method of first-stage screening is maternal factors, then measurement of biomarkers can be
reserved for only 70% of the population, and if some of the biomarkers are included in first-stage
screening then the need for the complete triple test can be reduced to 30–40% of the population.
With regard to the inhibin A, although this biomarker improved the prediction of preterm pre-eclampsia
provided by maternal factors alone (i.e. a detection rate of 49% vs. 60%), it did not improve the prediction
provided by biomarkers that included placental growth factor. In relation to small for gestational age
neonates, the competing risk model using the triple test at a risk cut-off point of 1 in 100 identified 46%
of cases of preterm small for gestational age neonates and 56% of cases of early small for gestational age.
Conclusions
The screening programme for pre-eclampsia study has demonstrated that risk assessment for pre-eclampsia
by current National Institute for Health and Care Excellence guidelines identifies approximately 30%
of women who would develop pre-eclampsia and about 40% of those who will develop preterm
pre-eclampsia, at a screen-positive rate of 10%. Compliance with the National Institute for Health and
Care Excellence recommendation that women at high risk for pre-eclampsia should be treated with aspirin
from the first trimester to the end of pregnancy was only 23%. Such low compliance may at least in part be
attributed to the generally held belief, based on the results of a meta-analysis in 2007, that aspirin reduces
the risk of pre-eclampsia by about 10% (Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS
Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual
patient data. Lancet 2007;369:1791–8). The performance of screening by the competing risk model
that combines maternal factors with biomarkers was superior to that of risk assessment by National
Institute for Health and Care Excellence guidelines. At the same screen-positive rate as for the National
Institute for Health and Care Excellence method, the detection rate for all pre-eclampsia in screening by
maternal factors, mean arterial pressure and serum pregnancy-associated plasma protein-A was 42.5%
and the detection rate for preterm pre-eclampsia by the triple test was 82.4%.
The strengths of the study are that (1) the study was a prospective examination of a large number
of pregnant women in several maternity units covering a wide spectrum of demographic and racial
characteristics; (2) > 90% of patients attending for routine care agreed to participate in the study,
measurement of all biomarkers was recorded in all cases and complete follow-up was obtained from
> 98% of patients; and (3) there was consistency in data collection through training of all investigators,
regular University College London Comprehensive Clinical Trials Unit monitoring, and external validation
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and quality assurance of biomarker measurements. A potential limitation of the study is lack of formal
health economic assessment. This was beyond the scope of this study, but it is currently being carried out.
The performance of screening for preterm pre-eclampsia by the competing risk model utilising the
triple test observed in this study is compatible with that reported in several previous studies of
singleton pregnancies at 11–13 weeks’ gestation. In four studies involving a combined total of 129,044
pregnancies, the detection rate of preterm pre-eclampsia was consistently approximately 75% at a
screen-positive rate of 10% (Wright D, Tan MY, O’Gorman N, Poon LC, Syngelaki A, Wright A,
Nicolaides KH. Predictive performance of the competing risk model in screening for preeclampsia.
Am J Obstet Gynecol 2019;220:199.e1–199.e13). None of these studies found evidence that pregnancy-
associated plasma protein-A improved screening achieved by the triple test.
Recent evidence suggests that first-trimester risk assessment should focus on prediction of preterm
pre-eclampsia. Aspirin is considerably more effective than previously thought in reducing the risk of
preterm pre-eclampsia, provided the daily dose of the drug is ≥ 100 mg and the gestational age at
onset of therapy is < 16 weeks (Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia.
Lancet. 2010;376:631–44). Against this background, there are ongoing debates about prediction and
prevention of preterm pre-eclampsia centred on two questions: (1) whether or not aspirin should be
recommended for all women or to a subpopulation of those women predicted to be at increased risk of
developing pre-eclampsia and (2) if a strategy of prediction and prevention is to be used, what method
should be used for prediction.
The arguments in favour of recommending aspirin to all women are that it avoids the need for
prediction and the whole population benefits from the prophylactic treatment with aspirin. Arguments
against this are that (1) compliance is likely to be worse when aspirin is applied to the whole population
than when recommended to a subpopulation selected, and counselled, based on risk and (2) there is a
need to balance the benefit from aspirin in prevention of preterm pre-eclampsia with potential harm
due to haemorrhagic and other adverse effects. Assuming all women took aspirin, an incidence of
preterm pre-eclampsia of 0.8% and a relative risk reduction of 60%, 208 women would be exposed to
aspirin for every case of preterm pre-eclampsia prevented. Using risk stratification with maternal
factors, mean arterial pressure, uterine artery pulsatility index and placental growth factor with the
same screen-positive rate as National Institute for Health and Care Excellence, 16 women would
be exposed to aspirin to prevent one case compared with 30 women using the National Institute for
Health and Care Excellence guidelines.
Regarding the method of prediction, the debate centres around screening performance, costs and
practical issues of implementation.
The main focus of this report has been on the detection rate achieved from the competing risk model
compared with that of the National Institute for Health and Care Excellence method. For the same
screen-positive rate as National Institute for Health and Care Excellence method, the detection rate
for preterm pre-eclampsia achieved by combining maternal factors with mean arterial pressure, uterine
artery pulsatility index and placental growth factor is 79.6% (95% confidence interval 72.7% to 86.5%)
compared with 44.1% (95% confidence interval 35.7% to 52.6%) using the National Institute for Health
and Care Excellence method. Using these estimates, with an incidence of preterm pre-eclampsia of
0.8%, the positive predictive values are 1 in 16 compared with 1 in 29 for the competing risk model and
National Institute for Health and Care Excellence method, respectively. Among women who screen
negative, the proportions with preterm pre-eclampsia (i.e. 1 – negative predictive value) are 1 in
550 and 1 in 200 for the competing risk model and National Institute for Health and Care Excellence
method, respectively.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxx
The main argument against the use of risk algorithms, such as the competing risk model, is that they
are too complex to use in practice. Simple methods, such as the National Institute for Health and Care
Excellence criteria or cut-off points applied to biomarker measurements or their ratios, should be
preferred because they are easy to implement in practice. Indeed, the essential features of our approach
of using Bayes’ theorem to update likelihoods from biomarker multiple of the median values to update
a prior based on maternal factors have been used for many decades in screening for aneuploidies.
These algorithms have been built into commercial software used extensively in practice. The commercial
software suppliers have implemented the competing risk model for pre-eclampsia screening into their
software systems.
Regarding the approaches based on application of cut-off points to individual markers or ratios of
different markers, the following points need to be considered. First, they do not provide individualised
risks for decision-making. Second, their performance is inferior to approaches based on probability
theory to make optimal use of the available information. Last, because biomarkers are affected by
covariates such as ethnicity, they are likely to be inequitable in the way they perform across different
groups within the population.
In clinical implementation of the competing risk model, recording maternal characteristics, measurement
of blood pressure and hospital attendance at 11–13 weeks’ gestation for ultrasound examination are
an integral part of routine antenatal care. Measurement of uterine artery pulsatility index can be carried
out by the same sonographers and machines used for the routine scan at 11–13 weeks’ gestation;
however, the sonographers will require training to carry out this test and the measurement would add
2–3 minutes to the current 20–30 minutes used for the scan. Serum placental growth factor can be
measured in the same blood sample and by the same automated platforms that are currently used for
measurement of pregnancy-associated plasma protein-A, as part of routine clinical practice in screening
for trisomies in all maternity hospitals in England; however, there is an additional cost for the reagents.
In conclusion, the screening programme for pre-eclampsia study has demonstrated that the performance
of first trimester screening for pre-eclampsia by a combination of maternal factors and biomarkers
is superior to that achieved by the risk assessment method recommended by the current National
Institute for Health and Care Excellence guidelines and it also predicts a high proportion of small for
gestational age neonates.
Future research
Future research should focus on prospective evaluation of (1) the Bayes’ theorem-based model in
populations who are dissimilar to the research population described in this study; (2) the proposed
two-stage screening approach and identification of potential biomarkers for further improvement of
the competing risk model; and (3) implementation in different clinical set-ups and economic assessment
of the new method of screening.
Trial registration
This trial is registered as ISRCTN83611527.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council
and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and
Mechanism Evaluation; Vol. 7, No. 8. See the NIHR Journals Library website for further project information.
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Pre-eclampsia, which affects 2–3% of pregnancies, is a major cause of maternal and perinatal morbidity
and mortality.1–4 Pre-eclampsia can be subdivided into preterm pre-eclampsia, requiring delivery before
37 weeks’ gestation, and term-pre-eclampsia, with delivery at ≥ 37 weeks’ gestation. Preterm pre-
eclampsia is associated with a higher incidence of adverse outcome.5 Globally, 76,000 women and
500,000 babies die each year from pre-eclampsia.
Obstetricians managing women with preterm pre-eclampsia are faced with the challenge of balancing
the need for achieving fetal maturation in utero with the risks to the mother and fetus from continuing
the pregnancy longer. These risks include progression to eclampsia, development of placental abruption
and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. On the other hand, preterm
delivery is associated with higher infant mortality rates and increased morbidity resulting from babies
born small for gestational age (SGA), thrombocytopenia, bronchopulmonary dysplasia, cerebral palsy
and an increased risk of various chronic diseases in adult life. Women who have experienced pre-
eclampsia may also face additional health problems in later life, as the condition is associated with an
increased risk of death from future cardiovascular disease, hypertension, stroke, renal impairment,
metabolic syndrome and diabetes.
Low-dose aspirin for the prevention of pre-eclampsia
Several trials have been carried out in the last 30 years that have investigated the potential benefit
of prophylactic use of low-dose aspirin in the prevention of pre-eclampsia.6 These studies were
heterogeneous in selection criteria, gestational age at onset, dose of aspirin and outcome measures.
A meta-analysis of these trials concluded that low-dose aspirin in high-risk women for development
of pre-eclampsia reduces the risk by about 10%.6
Recent evidence suggests that the risk of preterm pre-eclampsia can be substantially reduced by the
prophylactic use of aspirin. The multicentre Aspirin for Evidence-Based Preeclampsia Prevention
(ASPRE) trial carried out by the same research team (i.e. LCP, DW and KHN) reported that in women
with singleton pregnancies at high risk for pre-eclampsia, aspirin (150 mg/day) compared with placebo
from 11–14 to 36 weeks’ gestation was associated with a 62% [95% confidence interval (CI) 26%
to 80%] reduction in the incidence of preterm pre-eclampsia, but had no significant effect on the
incidence of term pre-eclampsia.7 A systematic review and meta-analysis of 16 trials in a combined
total of 18,907 participants, including the ASPRE trial,7 reported that aspirin reduces the risk of
preterm pre-eclampsia by 67% (95% CI 43% to 81%) provided that the daily dose was ≥ 100 mg and
onset of therapy was < 16 weeks. Aspirin had no significant effect on incidence of term pre-eclampsia.1
Current NICE recommendation
In the UK, the high-risk group who are advised to take aspirin is determined according to the
guidelines8 of the National Institute for Health and Care Excellence (NICE).9 At the booking visit,
pregnant women are considered to be at high risk of developing pre-eclampsia if they have any one
major factor (i.e. history of hypertensive disease in a previous pregnancy, chronic kidney disease,
autoimmune disease, diabetes or chronic hypertension) or any two moderate factors (i.e. first
pregnancy, aged ≥ 40 years, interpregnancy interval of > 10 years, body mass index at first visit of
≥ 35 kg/m2 or a family history of pre-eclampsia).8
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Logistic regression
Methods for identifying women at high risk of pre-eclampsia using probability incorporating biomarkers
as well as maternal risk factors have been the subject of much research over the last 20 years. Most
of these methods use binary logistic regression models and treat pre-eclampsia as a binary outcome.
An extensive review of these methods and the development of new models have recently been undertaken
by the International Prediction of Pregnancy Complication Network.10
Competing risk model
The method that we have developed represents pre-eclampsia as an event in time and uses a survival
model for the gestational age at delivery with pre-eclampsia. In this approach, deliveries for reasons
other than pre-eclampsia are treated as censored observations. Given her maternal characteristics
(Mat-CHs) and biomarker measurements, each woman has a personalised distribution of gestational
age at delivery with pre-eclampsia. The risk of delivery with pre-eclampsia before any particular
gestational age can be determined from this personalised distribution. This method therefore allows
early, preterm and all pre-eclampsia to be incorporated in the same model.
Using a similar approach to that taken in risk assessment for aneuploidies,11 the model is specified in
terms of a prior distribution from Mat-CHs and likelihood functions from biomarker measurements.12–16
Data from biomarker measurements are used to update the prior distribution using Bayes’ theorem to
produce a posterior distribution. By chaining Bayes’ theorem, the posterior distribution can be updated
as new information becomes available at different stages in pregnancy. This way of specifying the
model therefore provides a framework for dynamic prediction. It also allows the different marker
combinations to be used within the same underling model and new markers to be included without the
need for a completely new model.
Objectives of the SPREE study
The objectives of the screening programme for pre-eclampsia (SPREE) study set out in our original
application were as follows.
Prediction algorithm
We aimed to finalise the competing risk model for prediction of pre-eclampsia from Mat-CHs together
with combinations of the following four biomarkers:
1. mean arterial pressure (MAP)
2. uterine artery pulsatility index (UTA-PI)
3. maternal serum placental growth factor (PLGF)
4. pregnancy-associated plasma protein-A (PAPP-A).
Comparisons with NICE
We aimed to make the following prespecified comparisons of predictive performance of the competing
risk model with that of the NICE method:
l Primary – for the same screen-positive rate (SPR) determined by the NICE method, comparison of
the detection rate (DR) for pre-eclampsia with delivery at any gestational age:
¢ NICE compared with a mini-combined test (i.e. Mat-CHs, MAP and PAPP-A).
l Secondary – for the same SPR determined by NICE, comparison of DRs of preterm pre-eclampsia:
¢ NICE compared with Mat-CHs, MAP and PLGF
¢ NICE compared with Mat-CHs, MAP, PLGF and UTA-PI
¢ NICE compared with Mat-CHs, MAP and PAPP-A.
INTRODUCTION
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Predictive performance
We aimed to assess the predictive performance of the competing risk model for prediction of
pre-eclampsia at < 34 weeks’ gestation, pre-eclampsia at < 37 weeks’ gestation, pre-eclampsia at
≥ 37 weeks’ gestation and pre-eclampsia with delivery at any gestational age.
Screening in two stages
We aimed to demonstrate the process of first-stage screening using a subset of markers and then
applying the complete test to a subpopulation selected from first-stage risks.
Evaluation and inclusion of additional biomarkers
We aimed to explore the potential value of another biomarker, inhibin A, in predicting pre-eclampsia.
Prediction of small for gestational age neonates
We aimed to assess of the performance of the competing risk model in the prediction of SGA neonates.
In addition, we included a meta-analysis of screening performance that combines data from the SPREE
study with two other data sets. One data set has a population of 35,948 women and is used in a model
development referred to as the American Journal of Obstetricians and Gynecology (AJOG) data.17 The
other data set has a population of 8775 women and is used in the quality study phase of the ASPRE
trial, referred to as the ASPRE Screening Quality Study (SQS) data. Predictive performance is also
included for the AJOG data and for the SPREE study.
The rest of the report is organised as follows. Chapter 2 explains the competing risk model and is
accompanied by a technical specification (see Appendix 1). Details of the SPREE study cohort study
and the methodology used for comparisons of the competing risk model with NICE guidelines are
described in Chapter 3. Results from the SPREE study and comparisons with the NICE method are
given in Chapter 4 and discussed in Chapter 5. Assessment of performance of risk calibration is
presented in Chapter 6. Decision analysis curves are presented in Chapter 7. Chapter 8 presents the
meta-analysis of the results from the SPREE study, along with those from AJOG and ASPRE SQS data
sets. Chapter 9 presents the application of two-stage screening. Chapter 10 shows, using inhibin A,
how an additional marker can be added to the model. Chapter 11 examines the performance of the
competing risk model in the prediction of SGA.
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Chapter 2 The competing risk model
The objective of this chapter is to provide a non-technical description of the competing risk modelfor assessing the risk of pre-eclampsia that would provide a conceptual understanding of the
approach that is accessible to non-statisticians. Sections of this chapter have been reprinted from Am J
Obstet Gynecol, 214/1, O’Gorman N,Wright D, Syngelaki A, Akolekar R,Wright A, Poon LC, Nicolaides KH,
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks’
gestation, 103.e1–103.e12, 2016, with permission from Elsevier.17
Description of the competing risk model
The competing risk model11 assumes that if the pregnancy was to continue indefinitely then all women
would develop pre-eclampsia and whether or not they do so before a specified gestational age depends
on competition between delivery before or after development of pre-eclampsia.18,19
Each woman has a personalised distribution of gestational age at delivery with pre-eclampsia, as illustrated
in Figure 1. The risks obtained from this distribution are probabilities of delivery with pre-eclampsia,
assuming no other-cause delivery. These are given by the area under the probability density curve, as
illustrated in Figure 1a, or the height of the cumulative distribution curve, as illustrated in Figure 1b.
The cumulative distribution curve on Figure 1b is the graph of the areas on Figure 1a as functions of
gestational age at delivery.
There are many approaches that can be taken to fitting models to obtain personalised distribution.
Our approach uses Bayes’ theorem to combine a prior distribution determined from maternal and
pregnancy characteristics that are available at the first trimester of pregnancy with likelihoods from
biomarkers measured during pregnancy. The benefit of this approach for risk assessment is that
biomarkers can be added at different times and the posterior distribution can be updated with further
information as the pregnancy progresses. If no biomarker information is available, then risks can be
obtained from the prior model. From the model development perspective, new biomarkers can be
incorporated by augmenting the likelihood model without the need for a completely new model. This
facilitates extension of the model through the addition of new biomarkers. This report concerns biomarkers
measured in the first trimester. The full model includes biomarkers measured in the second and third
trimesters of pregnancy.
Prior model based on maternal factors
Figure 2 illustrates the prior distribution of gestational age at delivery with pre-eclampsia for three different
scenarios. Figure 2a shows the reference distribution that applies to a white, nulliparous woman with no
family history of pre-eclampsia, aged ≤ 35 years and with a weight of 69 kg and a height of 164 cm. Figure 2b
shows the distribution for a woman with low-risk factors, resulting in a shift of the mean to the right by 6.7
weeks and, therefore, a reduction in risk of delivery with pre-eclampsia at < 40 weeks’ gestation. Figure 2c
shows the distribution for a woman with high-risk factors, resulting in a shift of the mean to the left by
15.3 weeks and, therefore, an increase in risk of delivery with pre-eclampsia at < 40 weeks’ gestation.11
Multiples of the median of biomarkers
The use of multiple of the median (MoM) values as standardised biomarker measures has a long
history in screening that goes back over 40 years to early work on screening for anencephaly and spina
bifida.20 It is the established approach for standardisation incorporated in many software systems.
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The purpose of this standardisation is to remove the effects of characteristics (e.g. gestational age,
weight and ethnicity) associated with the individual being measured and characteristics associated with
the measurement instrument. If y denotes the measurement of the biomarker of a particular individual
and m the median value given the characteristics of this individual, then the MoM value is given by
MoM = y/m. MoM values are generally obtained from regression models of log-transformed biomarker
values. They are the antilogarithm of the errors or residuals from the regression model.
An important property of MoM values for our purposes is that, given the gestation of delivery with
pre-eclampsia, MoM values can be assumed to be conditionally independent of the covariates included
in the prior model. This is achieved by ensuring that MoM values are standardised for the covariates
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FIGURE 1 Personalised distribution of gestational age at delivery with pre-eclampsia. Risk of delivery with pre-eclampsia
before 37 weeks’ gestation is shown in the shaded area under the probability density (a) and the height of the cumulative
distribution (b). The area shaded blue is 0.05 or 1 in 20 and this is the risk of pre-eclampsia with delivery before
37 weeks’ gestation.
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Likelihood functions for biomarker measurements
The likelihood is specified in terms of the distribution of log10 transformed MoM values. Figure 3 shows
the fitted model for the biomarker PAPP-A. For a given value of PAPP-A MoM, the likelihood of a
particular value of gestational age at delivery with pre-eclampsia is given by the height of the Gaussian
curve. This is illustrated for cases where PAPP-A MoM is 0.3 and 1.5 in Figure 4.
Risk 0.018
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FIGURE 2 Prior distributions for three scenarios. The shaded areas show the risks of pre-eclampsia with delivery before
40 weeks’ gestation assuming no other cause for delivery. (a) Scenario 1 (age: 25 years, height: 164 cm, weight: 69 kg,
race: white, family history of pre-eclampsia: no, parity: nulliparous, conception: spontaneous, medical conditions: none);
(b) scenario 2 (age: 34 years, height: 170 cm, weight: 50 kg, race: white, family history of pre-eclampsia: no, parity: parous
without pre-eclampsia, previous gestation at delivery: 40 weeks’ gestation, pregnancy interval: 2 years, conception:
spontaneous, medical conditions: none); and (c) scenario 3 (age: 40 years, height: 140 cm, weight: 120 kg, race: black,
family history of pre-eclampsia: yes mother, parity: parous with pre-eclampsia, previous gestational age at delivery: 37 weeks’
gestation, pregnancy interval: 1 year, conception: spontaneous, medical conditions: none).
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FIGURE 4 Illustration of likelihood functions PAPP-A MoM values of 0.3 and 1.5. The heights shown in orange in parts
(a) and (c) are the values of the likelihood function for deliveries with pre-eclampsia at 26, 32, 38 and beyond 41.2 weeks’
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FIGURE 3 Distribution of PAPP-A by gestational age at delivery with pre-eclampsia. The points are observations of
gestational age at delivery with pre-eclampsia. The solid orange line is the broken stick model for mean log-MoM value of
PAPP-A. The histogram on the right shows log-MoM values for pregnancies where birth occurred without pre-eclampsia.
The Gaussian curves show the distribution of log-MoM PAPP-A conditionally on gestational age at delivery with
pre-eclampsia at 26, 32 and 38 weeks’ gestation, and for those beyond 42.8 weeks’ gestation for which the mean log-MoM
is zero. The data shown as points and in the histogram are from the SPREE study. The broken stick model is used to capture
the increasing effect on markers with increasing disease severity and the fact that gestations of delivery with pre-eclampsia
beyond term represent normality so therefore have a median of 1.0 as shown in the histogram on the right-hand side.
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FIGURE 4 Illustration of likelihood functions PAPP-A MoM values of 0.3 and 1.5. The heights shown in orange in parts
(a) and (c) are the values of the likelihood function for deliveries with pre-eclampsia at 26, 32, 38 and beyond 41.2 weeks’
gestation. The likelihood function is shown in parts (b) and (d).
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Application of Bayes’ theorem
The posterior distribution of gestational age at delivery with pre-eclampsia is obtained using Bayes’
theorem to combine the prior distribution from maternal and pregnancy characteristics with the
likelihood function from biomarker MoM values.
The posterior distribution is obtained by multiplying the prior probability density by the likelihood
function (Figure 5). Figures 5a–c show how the prior is modified by the likelihood for a MoM value of
PAPP-A of 0.3. At each gestation, the prior density shown in Figures 5a and d is multiplied by the
likelihood. For example, at 24 weeks’ gestation the prior probability is multiplied by about 6. In this
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FIGURE 5 Application of Bayes’ theorem in a case with PAPP-A MoM = 0.3 (a–c) and one with PAPP-A MoM= 1.5 (d–f).
The prior distribution is the same in both cases with a prior risk of pre-eclampsia before 37 weeks’ gestation of 0.05 or
1 in 20. With a PAPP-A MoM of 0.3, the posterior risk is 0.122. With a PAPP-A MoM of 1.5, the posterior risk is 0.033.
(continued )
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FIGURE 5 Application of Bayes’ theorem in a case with PAPP-A MoM = 0.3 (a–c) and one with PAPP-A MoM = 1.5 (d–f).
The prior distribution is the same in both cases with a prior risk of pre-eclampsia before 37 weeks’ gestation of 0.05 or
1 in 20. With a PAPP-A MoM of 0.3, the posterior risk is 0.122. With a PAPP-A MoM of 1.5, the posterior risk is 0.033.
(continued )
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To complete the posterior density, the area under the curve is made 1.0 by multiplying by a normalising
constant to produce the posterior shown in Figures 5c and f. Figures 5d–f show how the prior is modified
by the likelihood for a MoM value of PAPP-A of 1.5. In this case, densities at lower gestations are
decreased relative to those at higher gestations.
The area defining the risk can be computed for other gestations to produce a cumulative distribution
of risks that can be used as in individualised risk profile. This is illustrated in Figure 6, which shows
the cumulative distribution for the prior for the posterior with PAPP-A MoM equal to 0.3 and for the
posterior with PAPP-A MoM equal to 1.5.
The examples shown in Figures 5 and 6 illustrate the elements of our model using univariate examples.
The log-transformed biomarkers are assumed to follow a Gaussian distribution with a mean dependent
on the gestational age at delivery with pre-eclampsia according to a broken stick model. In general,
a multivariate Gaussian distribution is used and the association between biomarkers captured in the
correlations between markers. Technical details and parameter estimates of the algorithm for risk
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FIGURE 5 Application of Bayes’ theorem in a case with PAPP-A MoM = 0.3 (a–c) and one with PAPP-A MoM= 1.5 (d–f).
The prior distribution is the same in both cases with a prior risk of pre-eclampsia before 37 weeks’ gestation of 0.05 or
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FIGURE 6 Prior (dark blue) and posterior risk profiles for PAPP-A MoM = 0.3 (solid light blue) and 1.5 (dashed light blue).
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Face validity
The notion that if there were no deliveries from other causes then all pregnancies would deliver
with pre-eclampsia and that the distribution of gestations at deliveries with pre-eclampsia can occur
at unrealistically long gestational ages has raised questions. Some eminent workers in the field take
the view that these features are clinically plausible. Others argue that the model lacks face validity.
With this in mind, we remark that it is possible to formulate the model with a mixture of a continuous
distribution, up to say 44 weeks’ gestation, and a probability mass, at 44 weeks’ gestation. This
formulation, which gives the same risks, avoids unrealistically long gestations. From a pragmatic
perspective, the model provides a framework for risk calculation that has advantages over alternative
approaches in terms of flexibility and performance.
Comparison with other approaches
A simple method of identifying a high-risk group for pre-eclampsia is to use a classification based on
the presence of risk factors from maternal demographic characteristics and medical history. The current
NICE8 and American College of Obstetricians and Gynecologists21,22 guidelines adopt this method.
These have benefits in terms of simplicity; however, they do not give estimates of risk for counselling
and decision-making. The inclusion of extra information in terms of biomarker measurements is
problematic and predictive performance is limited.
Probability models can overcome these difficulties and there are numerous publications that use
logistic regression models for risk assessment. An extensive review of these logistic regression models
and the development of new models has recently been undertaken by the International Prediction of
Pregnancy Complication Network.10 These logistic regression models assume binary outcomes, and
separate models are needed for early-onset pre-eclampsia, for all pre-eclampsia and for late-onset
pre-eclampsia.12,14,15,23–29
Our approach, within the framework of competing risks, is based on a continuous model for the
gestational age at delivery with pre-eclampsia, treating births from causes other than pre-eclampsia as
censored observations using survival analyses.18,19 The same model covers pre-eclampsia at different
gestational ages of delivery and captures the way in which biomarkers show increasingly large effects
depending on the severity of pre-eclampsia. Implementing this model using Bayes’ theorem provides
a natural framework for dynamic prediction in which risk assessment is updated as new information
becomes available during pregnancy. Incorporation of biomarker information using likelihoods means
that new markers can be added by extending an existing model rather than developing a completely
new model.
Implementation
For the last three decades, commercial suppliers of equipment for ultrasound and laboratory measurements
have provided software systems for assessment of risk of aneuploidies. Computation of MoM values are
needed in these applications and calculations involving the combination of prior risks from Mat-CHs and
likelihoods from multivariate Gaussian distributions using Bayes’ theorem are involved.11 These systems
are used routinely for prenatal screening worldwide. The implementation of the competing risk model
is very similar to that involved in risk assessment for aneuploidies, including the computation of MoM
values, application of Bayes’ theorem and the need for effective quality assurance. The algorithm used
for risk calculations in the SPREE study has been implemented in many commercial software systems.
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Chapter 3 The SPREE study methods
The study was conducted according to protocol version 3.1 (14 November 2016).30
Study design and population
This was a prospective multicentre cohort study carried out in seven NHS maternity hospitals in
England, between 12 April 2016 and 15 December 2016.
The participating hospitals were King’s College Hospital, London; University Hospital Lewisham,
London; Medway Maritime Hospital, Gillingham; Homerton University Hospital, London;
North Middlesex University Hospital, London; Southend University Hospital, Essex; and The Royal
London Hospital, London.
Inclusion and exclusion criteria
Women aged > 18 years with a singleton pregnancy and a live fetus at the 11- to 13-week scan were
included in the study. Women who were unconscious or severely ill at the time of recruitment, those
with learning difficulties or serious mental illness and those with major fetal abnormality identified at
the 11- to 13-week scan were excluded from the study.
Research ethics approval
Approval for the study was obtained from the London–Surrey Borders Research Ethics Committee.
The study is registered with the ISRCTN registry, number 83611527.
Quality control of screening
Quality control of screening and verification of adherence to protocol were performed by the University
College London Comprehensive Clinical Trials Unit (UCL-CCTU).
Procedures
All eligible women with singleton pregnancies attending their routine hospital visit at 11+0 to 13+6 weeks’
gestation were given written information about the study and those who agreed to participate provided
written informed consent.
Gestational age was determined from the measurement of the fetal crown–rump length.31 Mat-CHs,
medical, obstetric and drug history were recorded, and maternal weight and height measured. The MAP
and UTA-PI were measured in accordance with standardised protocols;12,32 the measurements of MAP
were carried out by health-care assistants or research sonographers and measurements of UTA-PI were
performed by research sonographers. Maternal serum concentrations of PAPP-A and PLGF were measured
by one of two automated devices (DELFIA® Xpress analyser, PerkinElmer Life and Analytical Sciences Ltd,
Waltham, MA, USA, or BRAHMS KRYPTOR™ analyser, Thermo Fisher Scientific, Hennigsdorf, Germany).
Quality control was applied to achieve consistency of measurement of biomarkers across different
hospitals throughout the duration of the study.
Risks calculated using the competing risks model (see Chapter 2)17,33 were not made available to the
participants or their clinicians. The decision concerning administration of aspirin was made by the
attending clinicians in accordance with routine standard of care at each site and the information was
recorded in the research database both at the time of screening at 11–13 weeks’ gestation and
during collection of data on pregnancy outcome.
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All data on participant characteristics, biomarker values and outcome from each site were reported to
UCL-CCTU. The data, blinded to outcome, were then provided to the study statistician who:
(a) defined the screen-positive group in accordance with NICE criteria
(b) computed risks for all pre-eclampsia and preterm pre-eclampsia for the prespecified combinations
of biomarkers using the competing risks model17,33
(c) identified the group that was treated with aspirin (≥ 75 mg/day, starting at < 14 weeks’ gestation
and ending at ≥ 36 weeks’ gestation or at the time of earlier birth)
(d) examined associations between treatment using aspirin and baseline covariates, including the
components of the NICE method and biomarkers.
Details of the imputation methodology for dealing with the effects of aspirin and summaries of
Mat-CHs and treatment with aspirin were added to the statistical analysis plan. After the signed
statistical analysis plan and the data file containing data fields (a)–(c) were received and approved by
the UCL-CCTU research team, they provided data on pregnancy outcomes to the study statistician for
linking for the unblinded analysis.
Diagnosis of pre-eclampsia
Data on pregnancy outcome were collected from the hospital maternity records or the women’s general
medical practitioners. The obstetric records of all women with pre-existing or pregnancy-associated
hypertension were examined to determine the diagnosis of pre-eclampsia. This was based on the finding
of hypertension (i.e. systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg
on at least two occasions, 4 hours apart, developing after 20 weeks’ gestation in previously normotensive
women) and at least one of the following: proteinuria (i.e. ≥ 300mg/24 hours or protein-to-creatinine
ratio of ≥ 30mg/mmol or ≥ 2+ on dipstick testing), renal insufficiency (i.e. serum creatinine > 1.1 mg/dl or
twofold increase in serum creatinine in the absence of underlying renal disease), liver involvement (i.e.
blood concentration of transaminases to twice the normal level), neurological complications (e.g. cerebral
or visual symptoms), thrombocytopenia (i.e. platelet count < 100,000/µl) or pulmonary oedema.21,34
Outcome measures
The primary comparison was DR of risk assessment recommended by the NICE guidelines compared
with screening by a mini-combined test (i.e. Mat-CHs, MAP and PAPP-A) in the prediction of pre-
eclampsia occurring at any gestational age (i.e. all pre-eclampsia) after adjustment for the effect of
aspirin, for the same SPR determined by the NICE method. This combination of biomarkers was
selected because the test can be introduced without additional cost, as all NHS maternity hospitals in
England offer first-trimester combined screening for trisomies, which includes measurement of PAPP-A.
Key secondary comparisons were DR for preterm pre-eclampsia using NICE guidelines compared with
the competing risk model with the following marker combinations:
l Mat-CHs, MAP and PAPP-A
l Mat-CHs, MAP and PLGF
l Mat-CHs, MAP, UTA-PI and PLGF.
The combination of Mat-CHs and PLGF was selected because PLGF can be measured in the same
sample on the same machines used in screening for trisomies. In addition, in previous studies this
was found to be more effective than PAPP-A in the prediction of pre-eclampsia.35 The combination
of Mat-CHs, MAP, UTA-PI and PLGF was selected because in previous studies it was found to be the
most effective method of screening.
Statistical analysis
We proposed to recruit 16,850 women. On the assumptions of an incidence of pre-eclampsia of 2.6%
and a loss to follow-up rate of 5% there would be 16,000 women for evaluation. On the extreme
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assumption that 90% of NICE screen-positive patients and 10% of NICE screen-negative patients
would be treated with aspirin and that aspirin reduces the incidence of all pre-eclampsia by 50%, the
power to detect a 10% difference in DR between the NICE method and the mini-combined test in the
prediction of all pre-eclampsia at the one-sided 2.5% level would be > 80%.
We used McNemar’s test to compare the DR of the NICE method with that of the Bayes’ theorem-based
method. However, as some of the women who were screen positive according to NICE guidelines were
prescribed aspirin, which could have reduced the risk of pre-eclampsia, some of the patients in the
screen-positive group would have effectively been converted to false positives. Consequently, treating
NICE screen-positive women with aspirin would reduce the DR and bias the McNemar’s test against
the NICE method. Our approach to dealing with this was to apply multiple imputation of data on
the incidence of pre-eclampsia that would have occurred had it not been for the effect of treatment.
Markov chain Monte Carlo was used to impute incidence data and generate 10 complete data sets for
analysis.36 Estimates of DR were then pooled across data. The incidence of pre-eclampsia that would
have occurred had it not been for the effect of treatment was determined from a logistic regression
model dependent on NICE and centre, and that aspirin reduced the incidence with a prespecified
probability of 0.3 for all pre-eclampsia and 0.6 for preterm pre-eclampsia.7 Although these probabilities
were based on the results of the ASPRE trial, in which the daily dose of aspirin was 150 mg rather
than 75 mg (as recommended by NICE),8 we wanted to avoid any potential criticism of bias against the
NICE method by assuming that the effect of 75 mg was similar to that of higher doses of the drug.
The method of imputation and the choice of treatment effects were prespecified and documented prior
to receipt of the outcome data.
Additional evaluation of performance of the Bayes’ theorem-based method involved estimation of DRs
of pre-eclampsia at a fixed SPR of 10% for all 16 combinations of biomarkers. McNemar’s test was
applied to the effect of adding markers. No adjustments were made for the effects of aspirin in this
additional evaluation.
Markov chain Monte Carlo was implemented using the WinBUGS 1.4.3 software (MRC Biostatistics Unit,
Cambridge, UK). The WinBUGS model and a description of the methodology are given in Appendix 2.
The statistical software package R (The R Foundation for Statistical Computing, Vienna, Austria) was
used for data analyses with the MICE package, pooling estimates across the 10 complete data sets using
the function pool.scalar. Results were reported according to standards for the reporting of diagnostic
accuracy studies guidelines.37
Public and patient involvement
Public and patient involvement input into this study was particularly important to (1) identify possible
barriers to recruitment, (2) evaluate acceptability of early screening, (3) understand the implications of
classifying somebody as screen positive and (4) ensure that findings are disseminated and implemented
appropriately.
Melissa Green, Chief Executive Officer of Bliss, and Jane Fisher, Director of Antenatal Results and
Choices, were fully involved with our study and were full, independent members of the Study Steering
Group. They contributed to the development of the research question, to the application and provided
input into the study from funding through to reporting of the findings.
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Chapter 4 The SPREE study results
Study participants
During the study period, a total of 20,168 pregnant women attended one of the participating hospitals for
assessment at 11–13 weeks’ gestation. Of the 18,089 women who provided written informed consent,
17,051 were eligible to participate in the study and were screened for pre-eclampsia. Outcome data were
obtained from 16,747 women (Figure 7). The baseline characteristics of the participants are given in Table 1.
Pre-eclampsia developed in 473 (2.8%) pregnancies; in 142 (0.8%) cases, this was preterm pre-eclampsia.37
Intake of aspirin
Aspirin from < 14 weeks’ gestation to delivery or 36 weeks’ gestation was taken by 749 (4.5%) of
16,747 women in the study population. The daily dose was 75 mg in 730 (97.5%) women and 150 mg
in 19 (2.5%) women. Aspirin was taken by 400 (23.2%) women in the NICE screen-positive group
and 349 (2.3%) women in the NICE screen-negative group. The reported reasons for treatment in the
latter group were previous history of miscarriage (n = 153), stillbirth (n = 26), fetal growth restriction
(n = 25), placental abruption (n = 8), thrombophilia (n = 18), cardiovascular surgery (n = 3), family
history of pre-eclampsia (n = 6), current pregnancy conceived by in vitro fertilisation (n = 34), high body
mass index (n = 21), low serum PAPP-A found at screening for fetal trisomies (n = 47), one episode of
high blood pressure in the first trimester of pregnancy (n = 6), medical history of Lynch syndrome
(n = 1) and Raynaud’s disease (n = 1).
Attended scan clinic at 11–13 weeks
(n = 20,168)







• Aged < 18 years, severely ill, learning diff iculties,
    multiple pregnancy, n = 389
• Declined participation in research, n = 1690
Excluded
• Fetal death, multiple pregnancy, major defects,
    crown–rump length < 45 mm or < 84 mm, n = 1035
• Withdrawal of consent, n = 3
Excluded
• No follow-up, n = 304
FIGURE 7 Screening and follow-up.
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Primary comparison
Classification into screen positive and screen negative by the NICE method and the mini-combined test
stratified by outcome and aspirin treatment is shown in Table 2. With regard to Table 2, it is notable
that when using a fixed overall SPR and the results are stratified by aspirin, there is a substantial
imbalance between the SPRs obtained using the NICE method and those using the mini-combined test
in the aspirin and no-aspirin groups. If the risk cut-off point is chosen so that the SPRs for the NICE
method and the mini-combined test are the same, then the contingency results given in Table 3 are
obtained. For the aspirin group, this shows a significant benefit for the mini-combined test over the
NICE method (p = 0.003 without imputation for aspirin and p = 0.034 with imputation, assuming
RRR = 0.3). For the no-aspirin group the mini-combined test is superior to the NICE method (p < 0.001).38
TABLE 1 Baseline characteristics of study participants
Characteristic Total (N= 16,747)
Gestational age at screening (weeks), median (IQR) 12.8 (12.4–13.2)
Age (years), median (IQR) 31.5 (27.4–35.1)
Body mass index (kg/m2), median (IQR) 24.7 (22.0–28.7)
Racial origin, n (%)
White 12,112 (72.3)
Black 2404 (14.4)
South Asian 1384 (8.3)




Assisted by use of ovulation drugs 126 (0.8)
In vitro fertilisation 575 (3.4)
Cigarette smoker, n (%) 1132 (6.8)
Mother had pre-eclampsia, n (%) 543 (3.2)
Medical history, n (%)
Chronic hypertension 143 (0.85)
Systemic lupus erythematosus/antiphospholipid syndrome 40 (0.24)
Diabetes 119 (0.71)
Renal disease 29 (0.17)
Obstetrical history, n (%)
Nulliparous 7714 (46.1)
Multiparous without pre-eclampsia 8641 (51.6)
Multiparous with pre-eclampsia 392 (2.3)
Interval from last pregnancy (years), median (IQR) 2.7 (1.5–4.7)
Screen-positive by NICE guidelines, n (%) 1727 (10.3)
Aspirin intake during pregnancy, n (%) 749 (4.5)
NICE screen-positive group 400 (23.2)
NICE screen-negative group 349 (2.3)
IQR, interquartile range.
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TABLE 2 Contingency tables according to screening outcome by the NICE method and the mini-combined test with screen positive rate determined by NICE
Screening outcome
Mini-combined test
All outcomes Pre-eclampsia No pre-eclampsia
Positive (n) Negative (n) Total (n) Per cent Positive (n) Negative (n) Total (n) Per cent Positive (n) Negative (n) Total (n) Per cent
All pregnancies
NICE Positive (n) 824 903 1727 10.3 119 25 144 30.4 705 878 1583 9.7
Negative (n) 903 14,117 15,020 89.7 83 246 329 69.6 820 13,871 14,691 90.3
Total (n) 1727 15,020 16,747 202 271 473 1525 14,749 16,274
Per cent 10.3 89.7 42.7 57.3 9.4 90.6
Aspirin
NICE Positive (n) 256 144 400 53.4 45 8 53 73.6 211 136 347 51.3
Negative (n) 48 301 349 46.6 10 9 19 26.4 38 292 330 48.7
Total (n) 304 445 749 55 17 72 249 428 677
Per cent 40.6 59.4 76.4 23.6 36.8 63.2
No aspirin
NICE Positive (n) 568 759 1327 8.3 74 17 91 22.7 494 742 1236 7.9
Negative (n) 855 13,816 14,671 91.7 73 237 310 77.3 782 13,579 14,361 92.1
Total (n) 1423 14,575 15,998 147 254 401 1276 14,321 15,597
Per cent 8.9 91.1 36.7 63.3 8.2 91.8
Note













































































































































































































































































































































TABLE 3 Contingency tables according to screening outcome by NICE and the mini-combined test
Screening outcome
Mini-combined test
All outcomes Pre-eclampsia No pre-eclampsia
Positive (n) Negative (n) Total (n) Per cent Positive (n) Negative (n) Total (n) Per cent Positive (n) Negative (n) Total (n) Per cent
Aspirin
NICE Positive (n) 319 81 400 53.4 52 1 53 73.6 267 80 347 49.9
Negative (n) 81 286 349 46.6 12 7 19 26.4 69 279 348 50.1
Total (n) 400 367 749 64 8 72 336 359 695
Per cent 53.4 49.0 88.9 11.1 48.3 51.7
No aspirin
NICE Positive (n) 544 783 1327 8.3 74 17 91 22.7 470 766 1236 7.9
Negative (n) 783 13,888 14671 91.7 65 245 310 77.3 718 13,643 14,361 92.1
Total (n) 1327 14,671 15998 139 262 401 1188 14,409 15,597
Per cent 8.3 91.7 34.7 65.3 7.6 92.4
Note








































Table 4 summarises the results with and without multiple imputation of adjust for the effect of
aspirin. Without imputation, the SPR using the NICE method was 10.3% (1727/16,747) and the DR for
all pre-eclampsia was 30.4% (95% CI 26.3% to 34.6%). In screening by the mini-combined test using
a combination of Mat-CHs, MAP and PAPP-A, the DR of all pre-eclampsia was 42.7% (95% CI 38.2%
to 47.2%) and the difference in DR between the two methods was 12.3% (95% CI 8.1% to 16.5%).
The difference was overwhelmingly significant (p < 0.001). The false-positive rate (FPR) for the NICE
method was 9.7% (95% CI 9.3% to 10.2%) compared with 9.4% (95% CI 8.9% to 9.8%) for the mini-
combined test. For both the aspirin and no-aspirin subgroups shown in Table 4, the performance for the
mini-combined test is superior to that of the NICE method (p = 0.0028 for the aspirin group and
p < 0.0001 for the no aspirin group).
Imputation
The impact of aspirin treatment on McNemar’s test is to prevent pre-eclampsia and, therefore, transfer
events counts for aspirin in Table 2 from the pre-eclampsia to no pre-eclampsia. The data imputation
methodology reverses this process and, for those treated with aspirin, some observations are transferred
from the no pre-eclampsia to the pre-eclampsia data. The discordant cells positive with the mini-combined
TABLE 4 Performance of risk assessment for pre-eclampsia by NICE guidelines and screening by the competing risk
model with screen-positive and FPRs fixed according to NICE guidelines
No adjustment for aspirin Adjusted for aspirin
DR, % (95% CI)
Difference from NICE,
% (95% CI) DR, % (95% CI)
Difference from NICE,
% (95% CI)
All pregnancies (SPR = 10.3%)
All pre-eclampsia (n = 473)
NICE guidelines 30.4 (26.3 to 34.6) 31.6 (27.3 to 35.9)
Mat-CHs +
MAP + PAPP-A
42.7 (38.2 to 47.2) 12.3 (8.1 to 16.4) 42.8 (38.4 to 47.3) 11.2 (6.9 to 15.6)
Preterm pre-eclampsia (n = 142)
NICE guidelines 40.8 (32.8 to 48.9) 44.1 (35.7 to 52.6)
Mat-CHs +
MAP + PAPP-A
53.5 (45.3 to 61.7) 12.7 (4.7 to 20.7) 53.5 (45.5 to 61.6) 9.4 (0.1 to 18.2)
Mat-CHs +
MAP + PLGF
69.0 (61.4 to 76.6) 28.2 (19.4 to 37.0) 67.3 (59.7 to 75.0) 23.2 (13.2 to 33.3)
Mat-CHs +
MAP +UTA-PI + PLGF
82.4 (76.1 to 88.7) 41.6 (33.2 to 49.9) 79.6 (72.7 to 86.5) 35.5 (25.2 to 45.8)
Nulliparous (SPR = 12.7%)
All pre-eclampsia (n = 284)
NICE guidelines 21.5 (16.7 to 26.3) 22.3 (17.4 to 27.2)
Mat-CHs +
MAP + PAPP-A
35.9 (30.3 to 41.5) 14.4 (9.0 to 19.8) 36.1 (30.6 to 41.7) 13.8 (8.4 to 19.3)
Preterm pre-eclampsia (n = 75)
NICE guidelines 29.3 (19.0 to 39.6) 31.6 (21.1 to 42.2)
Mat-CHs +
MAP + PAPP-A
48.0 (36.7 to 59.3) 18.7 (6.0 to 31.3) 48.6 (37.3 to 60.0) 17.0 (4.2 to 29.8)
Mat-CHs +
MAP + PLGF
65.3 (54.6 to 76.1) 36.0 (23.4 to 48.6) 64.5 (53.5 to 75.5) 32.8 (19.3 to 46.4)
Mat-CHs +
MAP +UTA-PI + PLGF
77.3 (67.9 to 86.8) 48.0 (36.1 to 59.9) 75.7 (65.7 to 85.7) 44.0 (30.9 to 57.2)
continued
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test and negative with the NICE method (n = 38) and negative with the mini-combined test and positive
with the NICE method (n = 136) is the no pre-eclampsia data that have an impact on McNemar’s test.
Owing to the larger number in the negative mini-combined test and positive NICE method cells,
the effect of the imputation is to correct a negative bias against the NICE method. Imputation was
undertaken using the Markov chain Monte Carlo method, as described in Appendix 2.
The results of multiple imputation of data on the incidence of all pre-eclampsia that would have occurred
had it not been for the effect of treatment with aspirin are shown in Figure 8. After adjustment for the
effect of aspirin (i.e. a 30% reduction in the rate of all pre-eclampsia) in those receiving this drug the DR
TABLE 4 Performance of risk assessment for pre-eclampsia by NICE guidelines and screening by the competing risk
model with screen-positive and FPRs fixed according to NICE guidelines (continued )
No adjustment for aspirin Adjusted for aspirin
DR, % (95% CI)
Difference from NICE,
% (95% CI) DR, % (95% CI)
Difference from NICE,
% (95% CI)
Parous (SPR = 8.3%)
All pre-eclampsia (n = 189)
NICE guidelines 43.9 (36.8 to 51.0) 45.2 (37.9 to 52.6)
Mat-CHs +
MAP + PAPP-A
51.9 (44.7 to 59.0) 7.9 (1.7 to 14.2) 51.7 (44.6 to 58.7) 6.4 (–0.3 to 13.1)
Preterm pre-eclampsia (n = 67)
NICE guidelines 53.7 (41.8 to 65.7) 57.1 (44.9 to 69.3)
Mat-CHs +
MAP + PAPP-A
61.2 (49.5 to 72.9) 7.5 (–2.1 to 17.0) 60.3 (48.9 to 71.6) 3.2 (–8.5 to 14.9)
Mat-CHs +
MAP + PLGF
80.6 (71.1 to 90.1) 26.9 (16.3 to 37.5) 77.4 (67.3 to 87.4) 20.2 (6.9 to 33.5)
Mat-CHs +
MAP +UTA-PI + PLGF
85.1 (76.5 to 93.6) 31.3 (20.2 to 42.5) 81.0 (71.3 to 90.6) 23.8 (9.6 to 38.1)
–5
10.9% (6.7% to 15.1%)
11% (6.8% to 15.2%)
11.9% (7.7% to 16%)
11% (6.8% to 15.2%)
12.2% (8.1% to 16.3%)
10.7% (6.5% to 14.9%)
10.5% (6.2% to 14.7%)
10.8% (6.7% to 15%)
11.8% (7.7% to 15.9%)
11.6% (7.5% to 15.7%)
Pooled: 11.2% (6.9% to 15.6%)
Without imputation: 12.3% (8.1% to 16.4%)
0 5 10
Difference in DR (%)
15 20
FIGURE 8 Difference in DRs for pre-eclampsia with delivery at any gestational age [mini-combined test (i.e. Mat-CHs,
MAP and PAPP-A) vs. NICE method] with relative risk reduction from aspirin of 30%. The first 10 rows give the results
for 10 imputed samples.
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of the NICE method was 31.6% (95% CI 27.3% to 35.9%) and that of the Bayes’ theorem-based method
was 42.8% (95% CI 38.4% to 47.3%). The difference between the two methods was 11.2% (95% CI 6.9%
to 15.6%) (see Table 4).
Sensitivity analysis for assumptions regarding the effect of aspirin is given in Appendix 3, Figure 20.
This shows that our conclusions are robust to the effect of aspirin and even in the most extreme
case when aspirin is assumed to be 100% effective in preventing pre-eclampsia there is a substantial
and overwhelmingly significant (p < 0.0001) improvement in DR using the mini-combined test
(vs. the NICE method).
Key secondary comparisons
The three prespecified secondary comparisons were the NICE method compared with the competing
risk model using maternal factors and the following biomarker combinations for the prediction of
preterm pre-eclampsia (i.e. pre-eclampsia with delivery before 37 weeks’ gestation):
1. Mat-CHs, MAP and PAPP-A
2. Mat-CHs, MAP and PLGF
3. Mat-CHs, MAP, UTA-PI and PLGF.
There were 142 women who delivered with preterm pre-eclampsia. Screening performance of
the competing risk model and the NICE method is summarised in Table 4 and shown in Figure 9.
After adjusting for the effect of aspirin, the DR of the NICE method for preterm pre-eclampsia was
44.1% (95% CI 35.7% to 52.6%), which was lower than that of the Bayes’ theorem-based method
using Mat-CHs, MAP and PAPP-A (53.5%, 95% CI 45.5% to 61.6%), Mat-CHs, MAP and PLGF (67.3%,
95% CI 59.6% to 75.0%), and Mat-CHs, MAP, PLGF and UTA-PI (79.6%, 95% CI 72.7% to 86.5%).
The difference in DRs (i.e. competing risk model –NICE method) was 9.4% (95% CI 0.1% to 18.2%)
using the mini-combined test, 23.2% (95% CI 13.2% to 33.3%) using Mat-CHs together with MAP and
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FIGURE 9 Receiver operating characteristic curves for prediction of preterm pre-eclampsia by the competing risk model.
The patient-specific risk is derived by a combination of Mat-CHs with the measurements of MAP and PAPP-A (orange
curve), MAP and PLGF (light blue curve) and MAP, PLGF and UTA-PI (dark blue curve). Performance of risk assessment
using NICE guidelines is shown as a horizontal interrupted black line.
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The results of multiple imputation of data on the incidence of preterm pre-eclampsia that would have
occurred had it not been for the effect of treatment with aspirin are shown in Figure 10. After adjustment
for the effect of aspirin (i.e. a 60% reduction in rate of preterm pre-eclampsia) in those receiving this drug,
the difference in DR of the three Bayes’ theorem-based methods from the NICE method was 10.5%
(95% CI 2.3% to 18.8%), 24.0% (95% CI 14.3% to 33.7%) and 35.1% (95% CI 25.1% to 45.0%), respectively.
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FIGURE 10 Results of multiple imputation of data on the incidence of preterm pre-eclampsia that would have occurred
had it not been for the effect of treatment with aspirin. The DR of risk assessment by the NICE guidelines is compared
with that of screening by a combination of Mat-CHs with the measurements of (a) MAP and PAPP-A; (b) MAP and PLGF;
and (c) MAP, PLGF and UTA-PI. (continued )
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Additional data on performance of the competing risk model
Table 5 provides data on the DR of early, preterm and term pre-eclampsia at a fixed SPR of 10% in
screening by various combinations of biomarkers. Table 6 presents an analysis of the incremental
benefit in DR of individual biomarkers when added to a specific combination of markers. In all cases
apart from the addition of PAPP-A, the addition of a biomarker improved the DR.
Additional figures of receiver operating characteristic curves for prediction of pre-eclampsia by the
competing risk model are provided in Appendix 4.
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FIGURE 10 Results of multiple imputation of data on the incidence of preterm pre-eclampsia that would have occurred
had it not been for the effect of treatment with aspirin. The DR of risk assessment by the NICE guidelines is compared
with that of screening by a combination of Mat-CHs with the measurements of (a) MAP and PAPP-A; (b) MAP and PLGF;
and (c) MAP, PLGF and UTA-PI.
TABLE 5 Detection rate with 95% CI for a SPR of 10% in screening for pre-eclampsia by various combinations of
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TABLE 5 Detection rate with 95% CI for a SPR of 10% in screening for pre-eclampsia by various combinations of


































































































Reproduced with permission from Tan et al.38 Contains public sector information licensed under the Open Government
Licence v3.0.
TABLE 6 Incremental benefit in DR of preterm pre-eclampsia (with 95% CI) for a SPR of 10% when one biomarker is
added to a specific combination of one or more biomarkers
Comparison of methods of screening
DR (%)
p-valueBefore After Difference (95% CI)
Mat-CHs vs. addition of MAP 41.55 49.30 7.75 (1.6 to 14.6) 0.0291
Mat-CHs vs. addition of UTA-PI 41.55 61.97 20.42 (12.9 to 28.5) < 0.0001
Mat-CHs vs. addition of PLGF 41.55 59.15 17.61 (10.1 to 25.7) < 0.0001
Mat-CHs vs. addition of PAPP-A 41.55 45.07 3.52 (–1.7 to 9.2) 0.2673
Mat-CHs and MAP vs. addition of PLGF 49.30 68.31 19.01 (11.7 to 27.0) < 0.0001
Mat-CHs and MAP vs. addition of UTA-PI 49.30 73.94 24.65 (16.7 to 33.0) < 0.0001
Mat-CHs, MAP and UTA-PI vs. addition of PLGF 73.94 81.69 7.75 (2.3 to 14.1) 0.0153
Mat-CHs, MAP and PLGF vs. addition of UTA-PI 68.31 81.69 13.38 (8.0 to 20.2) < 0.0001
Mat-CHs, UTA-PI and PLGF vs. addition of MAP 70.42 81.69 11.27 (5.3 to 18.2) 0.0014
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Chapter 5 The SPREE study discussion
Principal findings of this study
The SPREE study has demonstrated that risk assessment for pre-eclampsia as currently recommended
by NICE guidelines8 identifies approximately 30% of women who would develop pre-eclampsia and
about 40% of those that will develop severe pre-eclampsia leading to preterm birth, at a SPR of 10%.
Compliance with the NICE recommendation that women at high-risk for pre-eclampsia should be treated
with aspirin from the first trimester to the end of pregnancy was only 23%. Such low compliance may,
at least in part, be attributed to the generally held belief, based on the results of a meta-analysis in
2007,6 that aspirin reduces the risk of pre-eclampsia by only about 10%.
The performance of screening by competing risks model, which combines maternal factors with
biomarkers,17,33 was superior to that of risk assessment by NICE guidelines. At the same SPR as for
the NICE method, the DR for all pre-eclampsia in screening by Mat-CHs, MAP and serum PAPP-A was
42.5% and the DR for preterm pre-eclampsia by a combination of Mat-CHs, MAP, UTA-PI and PLGF
was 82.4%, which is significantly higher than that of the NICE guidelines.
Strengths and limitations of this study
The strengths of the study include prospective examination of a large number of pregnant women
in several maternity units covering a wide spectrum of demographic and racial characteristics. The
results are therefore likely to be generalisable across the UK. More than 90% of patients attending
for routine care agreed to participate in the study. Measurement of all biomarkers was recorded in all
cases and complete follow-up was obtained from > 98% of participants. Consistency in data collection
was maintained throughout the study period by ensuring adequate training for all investigators based
on standardised protocols, regular UCL-CCTU monitoring, and external validation and quality assurance
of biomarker measurements.
A potential limitation of the study is lack of formal health economic assessment concerning the
implementation of combined screening for pre-eclampsia. Such assessment was beyond the scope of
this study, but it is currently being carried out.
Comparison with results of previous studies
The performance of screening for preterm pre-eclampsia by the competing risks model, utilising
Mat-CHs, MAP, UTA-PI and PLGF, observed in this study is comparable to that reported in several
previous studies of singleton pregnancies at 11–13 weeks’ gestation.17,19,39,40 The algorithm was originally
developed from a study19 of 58,884 pregnancies. The DR of preterm pre-eclampsia was 77% at a FPR
of 10%.19 Subsequently, we used data from prospective screening in 35,948 pregnancies to update
the original algorithm. The DR of preterm pre-eclampsia was 75% at a FPR of 10%.17 The diagnostic
accuracy of this algorithm was examined in a prospective multicentre study39 of 8775 pregnancies.
The DR of preterm pre-eclampsia was 75% at a FPR of 10%.39 In the screened population in the ASPRE
trial,40 involving 25,797 pregnancies from 13 maternity hospitals in six countries, the DR of preterm
pre-eclampsia after adjustment for the effect of aspirin was 77% at a FPR of 9.2%.40 None of these
studies found evidence that PAPP-A improved screening achieved by MAP, UTA-PI and PLGF.
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Other first-trimester combined prediction models have been developed in different populations.
Specifically, two Spanish cohort studies27,29 have developed models with the use of Mat-CHs, UTA-PI,
MAP and biochemical markers that have demonstrated similar predictive performance in comparison
with the Bayes’ theorem-based model. In contrast, three combined prediction algorithms, established
from cohort studies in the USA, demonstrate lower predictive performance than the Bayes’ theorem-
based model.25,28,41
A recent systematic review has compared the performance of simple risk models (i.e. Mat-CHs only)
with that of specialised models that include specialised tests (e.g. measurements of MAP, UTA-PI and/or
biochemical markers) for the prediction of pre-eclampsia.42 Seventy models from 29 studies were
identified (17 models to predict pre-eclampsia of any gestation, 31 models to predict early-onset
pre-eclampsia and 22 models to predict late-onset pre-eclampsia). Among them, 22 were simple risk
models, whereas 48 were classified as specialised models. Comparing simple and specialised models, the
latter performed better than the simple models in predicting both early- and late-onset pre-eclampsia.42
The specialised models have been shown to increase the DR of pre-eclampsia by 18% (95% CI 0% to
56%) at a fixed FPR of 5% or 10%.42 Such results further confirm that our approach to screening using
a combination of various tests rather than a single test is better for the prediction of pre-eclampsia.
Implications on clinical practice
Recent evidence suggests that first-trimester risk assessment should focus on prediction of pre-eclampsia
leading to preterm birth primarily with the aim of preventing preterm birth through treatment with
aspirin from 11–13 weeks’ gestation. Aspirin is considerably more effective than previously thought in
reducing the risk of preterm pre-eclampsia, provided the daily dose of the drug is ≥ 100 mg and the
gestational age at onset of therapy is < 16 weeks.1 In the ASPRE trial,7,43 use of aspirin (150mg/day)
starting from 11–14 weeks’ gestation reduced the risk of preterm pre-eclampsia by 62% and a secondary
analysis of the trial reported that the reduction was even greater (75%) if the compliance was ≥ 90%.
Against this background, there are ongoing debates about prediction and prevention of preterm
pre-eclampsia centred on two questions: (1) whether or not aspirin should be recommended for all women
or to a subpopulation of those women predicted to be at increased risk of developing pre-eclampsia and
(2) if a strategy of prediction and prevention is to be used, what method should be used for prediction.
The arguments in favour of recommending aspirin to all women are that it avoids the need for prediction
and the whole population benefits from the prophylactic treatment with aspirin. Arguments against
this are that (1) compliance is likely to be worse when aspirin is applied to the whole population than
when recommended to a subpopulation selected, and counselled, based on risk and (2) there is a need to
balance the benefit from aspirin in prevention of preterm pre-eclampsia with potential harm from aspirin
due to haemorrhagic and other adverse effects. Assuming that the entire population took aspirin, an
incidence of 0.8% and a relative reduction in risk of preterm pre-eclampsia of 60%, 208 women would be
exposed to aspirin treatment for every case of preterm pre-eclampsia prevented. Using risk stratification
with Mat-CHs, MAP, UTA-PI and PLGF with the same SPR as NICE, 16 women would need to be
exposed to aspirin to prevent one case compared with 30 women using the NICE guidelines.
Regarding the method of prediction, the debate centres around screening performance, costs and
practical issues of implementation.
The main focus of this report has been on the DR achieved by using the competing risk model
compared with that of the NICE method. For the same SPR as NICE, the DR for preterm pre-eclampsia
achieved by combining Mat-CHs with MAP, UTA-PI and PLGF is 79.6% (95% CI 72.7% to 86.5%) compared
with 44.1% (95% CI 35.7% to 52.6%) when using the NICE method. Using these estimates and with
an incidence of preterm pre-eclampsia of 0.8% the positive predictive values are 1 in 16 compared with
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1 in 29 for the competing risk model and NICE method, respectively. Among women who screen
negative, the proportions with preterm pre-eclampsia (i.e. 1 – negative predictive value) are 1 in
550 compared with 1 in 200 for the competing risk model and NICE method, respectively.
The main argument against the use of risk algorithms, such as the competing risk model, is that they
are too complex to use in practice. Simple methods, such as the NICE criteria or cut-off points applied
to biomarker measurements or their ratios, should be preferred because they are easy to implement in
practice. In fact, the essential features of our approach of using Bayes’ theorem to update likelihoods
from biomarker MoM values to update a prior based on maternal factors have been used for many
decades in screening for aneuploidies. These algorithms have been built into commercial software
used extensively in practice. The commercial software suppliers have implemented the competing risk
algorithm for pre-eclampsia screening into their software systems.
Regarding the approaches based on application of cut-off points to individual markers or ratios of
different markers, the following points need to be considered. First, they do not provide individualised
risks for decision-making. Second, their performance is inferior to approaches based on probability
theory to make optimal use of the available information. Last, because biomarkers are affected by
covariates such as ethnicity, they are likely to be inequitable in the way they perform across different
groups within the population.
In the clinical implementation of the first-trimester combined test for preterm pre-eclampsia, recording
Mat-CHs and medical history, measurement of blood pressure and hospital attendance at 11–13 weeks’
gestation for an ultrasound scan are an integral part of routine antenatal care. Measurement of UTA-PI
can be carried out by the same sonographers and ultrasound machines used for the routine scan at
11–13 weeks’ gestation; however, the sonographers will require training to carry out this test and the
measurement would add 2–3 minutes to the current 20–30 minutes used for the scan. Serum PLGF
can be measured in the same blood sample and by the same automated platforms that are currently
used for measurement of serum PAPP-A as part of routine clinical practice in screening for fetal trisomies
in all maternity hospitals in England; however, there is an additional cost for the reagents. Extensive
research has established reference ranges for MAP, PLGF and UTA-PI, has described the Mat-CHs that
affect the measurements and has developed the infrastructure for auditing of results.44–46
One decade ago, effective first-trimester screening for fetal trisomies was implemented in all maternity
hospitals in the UK within a few months of the appropriate decision being taken by the UK National
Screening Committee and NICE.47 The same infrastructure can now be used to expand the aims of first-
trimester screening to include identification of women at high risk of developing preterm pre-eclampsia
and substantially reducing such risk through the prophylactic use of the appropriate dose of aspirin.48
Conclusion
The SPREE study has demonstrated that the performance of first trimester screening for pre-eclampsia
by a combination of maternal factors and biomarkers is superior to that achieved by the risk assessment
method recommended by the current NICE guidelines.
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Chapter 6 The SPREE study calibration
Calibration refers to how well the predictions from the model agree with the observed outcomes.For a well-calibrated model, among those women with a risk of 1 in n the incidence should be 1
in n. This property should also hold for subgroups defined in terms of previous pregnancy history and
maternal factors and biomarkers.
The objective of this chapter is to provide the predictive performance of the competing risk model17,33
for (1) all pre-eclampsia using Mat-CHs, MAP and PAPP-A (which was the prespecified primary
outcome in the SPREE study);38 (2) pre-eclampsia with delivery at < 34 weeks’ gestation (i.e. early
pre-eclampsia), pre-eclampsia with delivery at < 37 weeks’ gestation (i.e. preterm pre-eclampsia) and all
pre-eclampsia for various combinations of the biomarkers MAP, UTA-PI and PLGF in the SPREE study;38
and (3) the data set from another validation study of the competing risks model (i.e. ASPRE SQS).39
Methods
Calibration was assessed visually through a series of figures showing the estimated incidence against
that predicted from risk for pre-eclampsia at < 34 weeks’ gestation, < 37 weeks’ gestation and any
pre-eclampsia for screening by maternal factors and various combinations of biomarkers. The plots
were obtained by grouping the data into bins according to risk. The estimated incidence in each group
was then plotted against the incidence predicted from the risks within each group (i.e. the mean risk).35
Calibration, in the large, is a measure of whether the risks are generally too high or too low. This is
quantified by the estimated intercept from a logistic regression of incidence on the logit of risk with
the slope fixed at 1. The intercept is a measure of the deviation of the observed incidence from the
predicted. For perfectly calibrated risks, the intercept should be zero. If there is a general tendency
for underestimation, so that the observed incidence is larger than that predicted, the intercept will be
positive. Conversely, for overestimation the intercept will be negative.
The calibration slope assesses the calibration across the range of risks and is the slope of the
regression line of the logistic regression of incidence on the logit of risk. If the risk is well
calibrated then the slope should be 1.0. A slope < 1 means that the relationship between risk
and incidence is flatter than it should be. A calibration slope > 1 means that the relationship is
steeper than it should be.
The risks produced from our competing risks model17,33 are for delivery with pre-eclampsia before a
specific gestation, assuming no other cause for delivery. As other-cause deliveries are effectively censored
observations, the actual incidence of pre-eclampsia would be expected to be lower than predicted.
For early gestations, when there are few other-cause deliveries, the effects would be small. At later
gestations, with many other-cause deliveries, the effect of censoring may be substantial. Consequently,
we applied survival analysis and used a Kaplan–Meier49 estimate of incidence of delivery with
pre-eclampsia treating deliveries from other causes as censored observations. The incidence counts
were adjusted for the effect of censoring by multiplying the estimated incidence by the number of
observations in each bin. The analysis was undertaken using the R statistical software with the survival
package for Kaplan–Meier estimates of survival probabilities.
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Results
Calibration of risks for the mini-combined test: Mat-CHs, MAP and PAPP-A in the
SPREE study
Calibration plots of the predictive performance of the competing risk model for all pre-eclampsia using
Mat-CHs, MAP and PAPP-A in the SPREE study are shown in Figure 11. Figures 11a and c show the
incidence with no correction for censoring. Figures 11b and d show the Kaplan–Meier estimates of
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FIGURE 11 Calibration plots for screening using the competing risk model for prediction of all pre-eclampsia by
Mat-CHs, MAP and PAPP-A. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); (b) estimated incidence with adjustment for censoring for Mat-CHs, MAP and PAPP-A
(all pre-eclampsia); (c) observed/expected incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); and (d) observed/expected incidence with adjustment for censoring for Mat-CHs, MAP
and PAPP-A (all pre-eclampsia). (continued )
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The error bars are 95% CIs. The numbers in black shown above each interval are the number of
pregnancies in each bin. Those in orange are the incidence counts in each of the bins. Statistics for the
calibration-in-the-large intercept and the calibration slope are shown superimposed on Figure 11. The
light blue line shows where the risks are perfect predictors of incidence. The vertical dashed line is
the mean overall risk and the horizontal dashed line is the overall incidence. The histograms show the
distribution of risks for pregnancies with pre-eclampsia (orange) and without pre-eclampsia (light blue).
The figure at the bottom of each graph shows the estimated incidence/mean risk within each bin.
With no adjustment for censoring, risks were well calibrated and with adjustment for censoring the
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FIGURE 11 Calibration plots for screening using the competing risk model for prediction of all pre-eclampsia by
Mat-CHs, MAP and PAPP-A. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); (b) estimated incidence with adjustment for censoring for Mat-CHs, MAP and PAPP-A
(all pre-eclampsia); (c) observed/expected incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); and (d) observed/expected incidence with adjustment for censoring for Mat-CHs, MAP
and PAPP-A (all pre-eclampsia).
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Calibration of risks for the preterm pre-eclampsia using Mat-CHs, MAP, UTA-PI and PLGF
in the SPREE study
Calibration plots of the predictive performance of the competing risk model for preterm pre-eclampsia
using Mat-CHs, MAP, UTA-PI and PLGF in the SPREE study are shown in Figure 12. Calibration of risks
for the uncorrected and corrected incidence was good and the calibration slope was very close to 1.0.
However, there was a tendency for the risks to underestimate the incidence of pre-eclampsia.
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FIGURE 12 Calibration plots for screening using the competing risk model for prediction of preterm pre-eclampsia by
Mat-CHs, MAP, UTA-PI and PLGF. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP, UTA-PI
and PLGF (pre-eclampsia before 37 weeks’ gestation); (b) estimated incidence with adjustment for censoring for Mat-CHs,
MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation); (c) observed/expected incidence with no adjustment
for censoring for Mat-CHs, MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation); and (d) observed/expected
incidence with adjustment for censoring for Mat-CHs, MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation).
The histograms show the distribution of risks in pregnancies with pre-eclampsia before 37 weeks’ gestation (orange) and
those without delivery with pre-eclampsia before 37 weeks’ gestation (light blue). (continued )
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Calibration of risks for delivery with pre-eclampsia by combinations of biomarkers
in the SPREE study
Quantitative assessment of calibration in the prediction of pre-eclampsia with delivery at < 34 weeks’
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FIGURE 12 Calibration plots for screening using the competing risk model for prediction of preterm pre-eclampsia by
Mat-CHs, MAP, UTA-PI and PLGF. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP, UTA-PI
and PLGF (pre-eclampsia before 37 weeks’ gestation); (b) estimated incidence with adjustment for censoring for Mat-CHs,
MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation); (c) observed/expected incidence with no adjustment
for censoring for Mat-CHs, MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation); and (d) observed/expected
incidence with adjustment for censoring for Mat-CHs, MAP, UTA-PI and PLGF (pre-eclampsia before 37 weeks’ gestation).
The histograms show the distribution of risks in pregnancies with pre-eclampsia before 37 weeks’ gestation (orange) and
those without delivery with pre-eclampsia before 37 weeks’ gestation (light blue).
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TABLE 7 Calibration statistics for delivery with pre-eclampsia at < 34 weeks’ gestation
Method of screening Slope (95% CI) Intercept (95% CI)
Mat-CHs 0.891 (0.737 to 1.045) 0.401 (0.142 to 0.66)
Mat-CHs +MAP 0.974 (0.825 to 1.124) 0.549 (0.289 to 0.808)
Mat-CHs +UTA-PI 1.083 (0.934 to 1.231) 0.477 (0.214 to 0.739)
Mat-CHs + PLGF 0.781 (0.664 to 0.899) 0.362 (0.092 to 0.632)
Mat-CHs + PAPP-A 0.879 (0.735 to 1.023) 0.364 (0.103 to 0.624)
Mat-CHs +MAP +UTA-PI 1.188 (1.03 to 1.346) 0.64 (0.377 to 0.903)
Mat-CHs +MAP + PAPP-A 0.938 (0.799 to 1.077) 0.497 (0.235 to 0.759)
Mat-CHs +MAP + PLGF 0.815 (0.699 to 0.93) 0.473 (0.199 to 0.747)
Mat-CHs +MAP + PLGF +UTA-PI 0.921 (0.8 to 1.042) 0.486 (0.209 to 0.763)
Reprinted from Am J Obstet Gynecol, 220/2, Wright D, Tan MY, O’Gorman N, Poon LC, Syngelaki A, Wright A,
Nicolaides KH, Predictive performance of the competing risk model in screening for preeclampsia, 199.e1–199.e13,
2019, with permission from Elsevier.35
TABLE 8 Calibration statistics for delivery with pre-eclampsia at < 37 weeks’ gestation
Method of screening Slope (95% CI) Intercept (95% CI)
Mat-CHs 0.96 (0.837 to 1.083) 0.136 (–0.033 to 0.305)
Mat-CHs +MAP 1.032 (0.914 to 1.151) 0.252 (0.083 to 0.422)
Mat-CHs +UTA-PI 1.162 (1.042 to 1.283) 0.177 (0.007 to 0.348)
Mat-CHs + PLGF 0.904 (0.806 to 1.003) 0.127 (–0.048 to 0.301)
Mat-CHs + PAPP-A 0.943 (0.827 to 1.059) 0.111 (–0.059 to 0.281)
Mat-CHs +MAP +UTA-PI 1.248 (1.124 to 1.371) 0.303 (0.131 to 0.474)
Mat-CHs +MAP + PAPP-A 0.997 (0.886 to 1.108) 0.22 (0.05 to 0.391)
Mat-CHs +MAP + PLGF 0.937 (0.84 to 1.035) 0.224 (0.048 to 0.4)
Mat-CHs +MAP + PLGF +UTA-PI 1.044 (0.943 to 1.145) 0.23 (0.052 to 0.408)
TABLE 9 Calibration statistics for pre-eclampsia with delivery at any gestational age
Method of screening Slope (95% CI) Intercept (95% CI)
Mat-CHs 1.024 (0.928 to 1.121) –0.212 (–0.309 to –0.114)
Mat-CHs +MAP 1.111 (1.02 to 1.201) 0.01 (–0.089 to 0.108)
Mat-CHs +UTA-PI 1.115 (1.022 to 1.209) –0.057 (–0.155 to 0.041)
Mat-CHs + PLGF 0.96 (0.879 to 1.042) –0.072 (–0.172 to 0.028)
Mat-CHs + PAPP-A 0.983 (0.892 to 1.073) –0.086 (–0.184 to 0.012)
Mat-CHs +MAP +UTA-PI 1.225 (1.133 to 1.317) 0.029 (–0.07 to 0.128)
Mat-CHs +MAP + PAPP-A 1.075 (0.988 to 1.162) –0.005 (–0.104 to 0.094)
Mat-CHs +MAP + PLGF 1.034 (0.954 to 1.115) 0.003 (–0.097 to 0.103)
Mat-CHs +MAP + PLGF +UTA-PI 1.096 (1.015 to 1.177) 0.007 (–0.094 to 0.107)
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Calibration of risks in the ASPRE SQS
The data for the ASPRE SQS were derived from prospective screening for pre-eclampsia in 8775
women between February and September 2015 in 12 maternity hospitals in England, Spain, Belgium,
Italy and Greece.39 This study was carried out before the ASPRE trial7 and was primarily designed to
examine the feasibility of multicentre screening and establish methods for quality assurance of the
biomarkers. The algorithm used for screening was the same as in the SPREE study.17,33 The diagnosis
of pre-eclampsia was based on the previous criteria of the International Society for the Study of
Hypertension in Pregnancy,34 whereas the new wider definition was used in the SPREE study.21,34
Calibration plots of the predictive performance of the competing risk model for all pre-eclampsia using
Mat-CHs, MAP and PAPP-A in the ASPRE SQS are shown in Figure 13, and calibration plots of the
predictive performance of the model for preterm pre-eclampsia using Mat-CHs, MAP, UTA-PI and
PLGF in the ASPRE SQS are shown in Figure 14.
In screening by the mini-combined test, the risks overestimate the unadjusted incidence and are relatively
well calibrated for the adjusted incidence. In the case of screening by Mat-CHs, MAP, UTA-PI and PLGF
for preterm pre-eclampsia, adjustment for censoring makes very little difference and calibration is
generally good.
Discussion
This study has examined the predictive performance of the competing risk model17,33 in two prospective
screening studies (i.e. the SPREE study and the ASPRE SQS). The results demonstrate that in both the
SPREE study and the ASPRE SQS calibration of risks for pre-eclampsia was generally good, with the
calibration slope very close to 1.0. However, in the case of the SPREE study there was a tendency for
the risks to underestimate the incidence of pre-eclampsia. This was made worse when adjustments were
made for censoring. With the ASPRE SQS, calibration was improved with adjustment for censoring, with
no underestimation of risks.
Calibration refers to how well the predictions from the model agree with the observed outcomes.
Deviations between the predicted and observed outcome not only reflect on the accuracy of a given
model but could also be the consequence of differences between the studies used for development
of the model and the studies used for validation in terms of the below:
l methodology and accuracy of recording Mat-CHs and medical history, and the measurement
of biomarkers
l ascertainment and definition of the outcome measure.
Possible explanations for the differences in findings between the SPREE study and the ASPRE SQS
are that in the SPREE study we used the new criteria for defining pre-eclampsia, which results in a
higher incidence. In addition, the ascertainment was higher because the study was specifically designed
for this purpose. The ASPRE SQS focused on quality assurance of biomarkers in preparation for the
ASPRE trial.
The strengths of this study include that (1) it is a large prospective evaluation of the calibration of risks
from a prespecified algorithm, (2) the assessment of calibration allowed for the effect of censoring due
to births from causes other than pre-eclampsia and (3) it is a multicentre study with a diverse population,
making the results generalisable.
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FIGURE 13 Calibration plots for screening using the competing risk model for prediction of all pre-eclampsia by Mat-CHs,
MAP and PAPP-A for the ASPRE SQS. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); (b) estimated incidence with adjustment for censoring for Mat-CHs, MAP and PAPP-A
(all pre-eclampsia); (c) observed/expected incidence with no adjustment for censoring for Mat-CHs, MAP + PAPP-A
(all pre-eclampsia); and (d) observed/expected incidence with adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia). (continued )
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FIGURE 13 Calibration plots for screening using the competing risk model for prediction of all pre-eclampsia by Mat-CHs,
MAP and PAPP-A for the ASPRE SQS. (a) Estimated incidence with no adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia); (b) estimated incidence with adjustment for censoring for Mat-CHs, MAP and PAPP-A
(all pre-eclampsia); (c) observed/expected incidence with no adjustment for censoring for Mat-CHs, MAP + PAPP-A
(all pre-eclampsia); and (d) observed/expected incidence with adjustment for censoring for Mat-CHs, MAP and
PAPP-A (all pre-eclampsia).
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FIGURE 14 Calibration plots for screening using the competing risk model for prediction of preterm pre-eclampsia by
Mat-CHs, MAP and PAPP-A for the ASPRE SQS. (a) Estimated incidence with no adjustment for censoring for Mat-CHs,
MAP and PAPP-A (pre-eclampsia before 37 weeks); (b) estimated incidence with adjustment for censoring for Mat-CHs,
MAP and PAPP-A (pre-eclampsia before 37 weeks); (c) observed/expected incidence with no adjustment for censoring for
Mat-CHs, MAP and PAPP-A (pre-eclampsia before 37 weeks); and (d) observed/expected incidence with adjustment for
censoring for Mat-CHs, MAP and PAPP-A (pre-eclampsia before 37 weeks’ gestation). (continued )
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FIGURE 14 Calibration plots for screening using the competing risk model for prediction of preterm pre-eclampsia by
Mat-CHs, MAP and PAPP-A for the ASPRE SQS. (a) Estimated incidence with no adjustment for censoring for Mat-CHs,
MAP and PAPP-A (pre-eclampsia before 37 weeks); (b) estimated incidence with adjustment for censoring for Mat-CHs,
MAP and PAPP-A (pre-eclampsia before 37 weeks); (c) observed/expected incidence with no adjustment for censoring for
Mat-CHs, MAP and PAPP-A (pre-eclampsia before 37 weeks); and (d) observed/expected incidence with adjustment for
censoring for Mat-CHs, MAP and PAPP-A (pre-eclampsia before 37 weeks’ gestation).
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Chapter 7 The SPREE study decision
curve analysis
Previous chapters focus on the predictive performance of the model. This chapter examines theclinical utility of the model using decision curve analysis.
Methods
Decision curves are graphical displays of net benefit as a function of threshold probabilities. Each threshold
represents a risk at which a true positive is equivalent to avoiding a false positive. At one extreme, a
threshold of zero represents the position where true positive outweighs any number of false positives.
At the other extreme, a threshold of 1 represents the point at which avoidance of a false positive
outweighs any number of true positives. A threshold of 0.5 means that the avoidance of a false positive
equates to a true positive, so that the probability threshold that determines the decision is 0.5. For a











where n is the number of participants in the study.
The higher the net benefit the better. The maximum net benefit occurs when the DR for a given test is
100%, the FPR is zero and the net benefit is the same as the incidence.
If there is no screening test and all individuals are considered as negative then the net benefit is zero.











In prediction and prevention of preterm pre-eclampsia this would represent the policy of treating
everyone with aspirin.
Net benefits were computed and plotted using the R statistical software. A log-scale was used for the
probability threshold so that the lower values of most interest occupied a greater proportion of the scale.
The decision curves shown in dark blue in Figure 15 are for prediction of pre-eclampsia before 34 weeks’
gestation, before 37 weeks’ gestation and at any gestational age using the competing risk with different
combinations of markers. Screening for pre-eclampsia with delivery before 34 and 37 weeks’ gestation
was chosen for the purposes of examining policies of treatment with aspirin.
Results
Decision curves for pre-eclampsia with delivery before 34 and 37 weeks’ gestation for the SPREE study
data using the competing risk model with the following combinations of markers are shown in Figure 15:
l Mat-CHs and MAP
l Mat-CHs, MAP and PLGF
l Mat-CHs MAP and UTA-PI
l Mat-CHs, MAP, UTA-PI and PLGF.
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Decision curves for other marker combinations and for pre-eclampsia with delivery at any gestational
age are given in Appendix 5, Figure 87.
Discussion
In general, the decision curves for the combined test are superior to the policies of screening everyone
positive or screening everyone negative for the range of threshold probabilities that would seem
reasonable. The best performance is provided by the competing risk model incorporating Mat-CHs and
the triple test. It is notable that the net benefit of screening all positive is lower than that of screening






















































FIGURE 15 Decision curves for screening for pre-eclampsia with delivery before (a) 34 weeks’ gestation; and (b) 37 weeks’
gestation. The light blue curve is the decision curve for the policy of screening everyone positive. The pink line is the decision
curve for screening everyone negative.
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Chapter 8 Meta-analysis of performance
In this chapter we compare the performance of screening for pre-eclampsia in the SPREE study withtwo other data sets: (1) a population used for development of the algorithm, referred to as AJOG,17
and (2) a population like that of the SPREE study that was used for validation of the algorithm,
referred to as the ASPRE SQS.39 Details of these populations can be found in the original publications
and are summarised below.17,39
Methods
In all three populations there was prospective screening for pre-eclampsia in singleton pregnancies at
11+0 to 13+6 weeks’ gestation. Women aged > 18 years with a singleton pregnancy and a live fetus
at the 11- to 13-week scan were included in the study. Women who were unconscious or severely ill at
the time of recruitment, those with learning difficulties or serious mental illness and those with major
fetal abnormality identified at the 11- to 13-week scan were excluded from the study.
The visit at 11–13 weeks’ gestation included (1) recording of Mat-CHs and obstetric and medical
history,33 (2) measurement of maternal weight and height, (3) measurement of MAP by validated
automated devices and standardised protocol,32 (4) measurement of the left and right UTA-PI
by transabdominal colour Doppler ultrasound and calculation of the mean pulsatility index,12 and
(5) measurement of serum concentration of PLGF and PAPP-A (using a DELFIA Xpress analyser or
BRAHMS KRYPTOR analyser). Gestational age was determined from the fetal crown–rump length.31
The women gave written informed consent to participate in the studies, which were approved by the
relevant research ethics committee in each participating centre.
In this study and from each of the three data sets (i.e. the SPREE study, the ASPRE SQS and AJOG)
we included only pregnancies delivering a phenotypically normal live birth or stillbirth at ≥ 24 weeks’
gestation, and we excluded pregnancies with aneuploidies and major fetal abnormalities and those
ending in termination, miscarriage or fetal death before 24 weeks.
Population in AJOG
The data for this study were derived from prospective screening for adverse obstetric outcomes in
35,948 women attending for their routine first hospital visit in pregnancy at King’s College Hospital
or Medway Maritime Hospital.17 The diagnosis of pre-eclampsia was based on the previous criteria of
the International Society for the Study of Hypertension in Pregnancy.34 These include the finding of
hypertension (i.e. systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg on
at least two occasions, 4 hours apart, developing after 20 weeks’ gestation in previously normotensive
women) and proteinuria (i.e. ≥ 300 mg/24 hours or protein-to-creatinine ratio of ≥ 30 mg/mmol or
≥ 2+ on dipstick testing).
Population in the ASPRE SQS
The data for this study were derived from prospective screening for pre-eclampsia in 8775 women
and involved pregnancies in 12 maternity hospitals in England, Spain, Belgium, Italy and Greece.39
The women were screened between February and September 2015. This study was carried out before
the ASPRE trial7 and was primarily designed to examine the feasibility of multicentre screening and
establish methods for quality assurance of the biomarkers. The algorithm used for screening was
the one established in AJOG.17 The diagnosis of pre-eclampsia was based on the previous criteria of the
International Society for the Study of Hypertension in Pregnancy.34
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Population in the SPREE study
This was a prospective multicentre cohort study carried out in seven NHS maternity hospitals in England,
between April and December 2016.38 This study was specifically designed to examine the performance
of screening by the algorithm established in AJOG17 in comparison with that of the method advocated
by NICE.8 The diagnosis of pre-eclampsia was based on updated criteria of the International Society for
the Study of Hypertension in Pregnancy.21,34 This includes the finding of hypertension (i.e. systolic blood
pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg on at least two occasions, 4 hours
apart, developing after 20 weeks’ gestation in previously normotensive women) and at least one of the
following: proteinuria (i.e. ≥ 300 mg/24 hours or protein-to-creatinine ratio ≥ 30 mg/mmol or ≥ 2 + on
dipstick testing), renal insufficiency (i.e. serum creatinine > 1.1 mg/dl or a twofold increase in serum
creatinine in the absence of underlying renal disease), liver involvement (i.e. blood concentration of
transaminases to twice the normal level), neurological complications (e.g. cerebral or visual symptoms),
thrombocytopenia (i.e. platelet count < 100,000/µl) or pulmonary oedema.
Statistical analysis
Patient-specific risks of delivery with pre-eclampsia at < 32, < 37 and ≥ 37 weeks’ gestation and all
pre-eclampsia were calculated using the competing risks model17,33 to combine the prior distribution of
the gestational age at delivery with pre-eclampsia, obtained from Mat-CHs and medical history, with
MoM values of MAP, UTA-PI, PLGF and PAPP-A. The performance of screening in each of the three
data sets and in the combined total population was assessed. Heterogeneity was assessed using Q- and
I2-statistics.
Results
Maternal and pregnancy characteristics in AJOG, the ASPRE SQS and the SPREE study populations
are provided and compared in Table 10. The population in AJOG appears to be at higher risk of
pre-eclampsia than in the other two data sets. There were also significantly more black women and
fewer white women in the AJOG data set, as well as more women with chronic hypertension, diabetes
or a family history of pre-eclampsia and more nulliparous women and parous women with a previous
history of pre-eclampsia. Despite this increased risk in the AJOG data set, the observed incidence of
pre-eclampsia was decreased, raising the possibility of underascertainment.
TABLE 10 Maternal and pregnancy characteristics in the three populations
Variable AJOG (N= 35,948) ASPRE SQS (N= 8775) SPREE study (N= 16,451)
Maternal age (years), median (IQR) 31.3 (26.8–35.0) 31.5 (27.3–35.0)a 31.5 (27.4–35.1)a
Maternal weight (kg), median (IQR) 66.7 (59.0–77.2) 66.5 (59.0–77.0)b 67.0 (59.2–78.0)a
Maternal height (cm), median (IQR) 164.5 (160.0–169.0) 164.5 (160.0–169.0)b 165.0 (160.0–169.0)a
Body mass index (kg/m2), median (IQR) 24.5 (22.0–28.4) 24.5 (21.9–28.4)b 24.7 (22.0–28.7)a
Gestational age (weeks), median (IQR) 12.7 (12.3–13.1) 12.7 (12.3–13.1)a,b 12.9 (12.4–13.3)a
Racial origin, n (%) a,b a
White 25,879 (71.99) 6883 (78.44) 11,922 (72.47)
Black 6681 (18.59) 1090 (12.42) 2337 (14.21)
South Asian 1623 (4.51) 462 (5.26) 1361 (8.27)
East Asian 846 (2.35) 154 (1.75) 407 (2.47)
Mixed 919 (2.56) 186 (2.12) 424 (2.58)
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The DR for preterm pre-eclampsia at a fixed SPR of 10% in the three data sets is summarised in Figure 16.
The DR for pre-eclampsia at < 32, < 37 and ≥ 37 weeks’ gestation and all pre-eclampsia at a fixed SPR
of 10% by various combinations of biomarkers is given in Tables 11–14.
Receiver operating characteristics curves for the performance of screening for preterm pre-eclampsia
are given in Appendix 7.
Discussion
Differences in screening performance between studies, reflecting differences in study populations,
study design and measurement quality, are inevitable. However, the results of this analysis on
performance of screening show that there is little evidence of substantive differences in DRs across
the three data sets at a SPR of 10% (equivalent to that of NICE guidelines).
The combined results demonstrate that (1) the performance of screening is substantially better for
early pre-eclampsia and preterm pre-eclampsia than for term pre-eclampsia (DR by the triple test at a
10% SPR of 90% and 75% vs. 41%, respectively); (2) in preterm pre-eclampsia screening by Mat-CHs is
TABLE 10 Maternal and pregnancy characteristics in the three populations (continued )
Variable AJOG (N= 35,948) ASPRE SQS (N= 8775) SPREE study (N= 16,451)
Conception, n (%) a,b a
Natural 34,743 (96.65) 8483 (96.67) 15,765 (95.83)
Assisted by use of ovulation drugs 349 (0.97) 64 (0.73) 125 (0.76)
In vitro fertilisation 856 (2.38) 227 (2.59) 561 (3.41)
Medical history, n (%)
Chronic hypertension 561 (1.56) 100 (1.14)b 137 (0.83)a
Diabetes type 1 137 (0.38) 31 (0.35)b 46 (0.28)a
Diabetes type 2 188 (0.52) 37 (0.42)b 71 (0.43)a
SLE/APS 53 (0.15) 19 (0.22) 39 (0.24)a
Cigarette smokers, n (%) 3263 (9.08) 732 (8.34)b 1105 (6.72)a
Family history of pre-eclampsia, n (%) 1518 (4.22) 339 (3.86)a 535 (3.25)a
Parity, n (%) a,b a
Nulliparous 17,361 (48.29) 4127 (47.03) 7587 (46.12)
Parous with no previous
pre-eclampsia
17,311 (48.16) 4459 (50.81) 8483 (51.57)
Parous with previous pre-eclampsia 1276 (3.55) 189 (2.15) 381 (2.32)
Pre-eclampsia, n (%)
Total 1058 (2.94) 239 (2.72)a,b 473 (2.88)
Delivery < 37 weeks’ gestation 292 (0.81) 59 (0.67)a,b 142 (0.86)
Delivery < 32 weeks’ gestation 66 (0.18) 17 (0.19)b 33 (0.20)
APS, antiphospholipid syndrome; IQR, interquartile range; SLE, systemic lupus erythematosus.
a Significance value of p < 0.05 in comparison with the ASPRE SQS, SPREE study and AJOG.
b Significance value of p < 0.05 in comparison with the ASPRE SQS and SPREE study.
Note
Comparisons between outcome groups were by chi-square or Fisher’s exact test for categorical variables and
Mann–Whitney U-test for continuous variables.
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FIGURE 16 Detection rate for preterm pre-eclampsia at a fixed SPR of 10% in the three databases.
TABLE 11 Detection rate for pre-eclampsia at < 32 weeks’ gestation at a fixed SPR of 10%
Method of







Mat-CHs 50.00 (37.43 to 62.57) 52.94 (27.81 to 77.02) 51.52 (33.54 to 69.20) 52.59 (43.11 to 61.93)
MAP 60.61 (47.81 to 72.42) 70.59 (44.04 to 89.69) 69.70 (51.29 to 84.41) 61.21 (51.72 to 70.11)
UTA-PI 63.64 (50.87 to 75.13) 76.47 (50.10 to 93.19) 78.79 (61.09 to 91.02) 69.83 (60.61 to 78.00)
PLGF 77.27 (65.30 to 86.69) 70.59 (44.04 to 89.69) 63.64 (45.12 to 79.60) 72.41 (63.34 to 80.30)
PAPP-A 48.48 (35.99 to 61.12) 52.94 (27.81 to 77.02) 57.58 (39.22 to 74.52) 55.17 (45.66 to 64.41)
MAP, UTA-PI 75.76 (63.64 to 85.46) 88.24 (63.56 to 98.54) 87.88 (71.80 to 96.60) 82.76 (74.64 to 89.14)
MAP, PAPP-A 62.12 (49.34 to 73.78) 70.59 (44.04 to 89.69) 69.70 (51.29 to 84.41) 65.52 (56.12 to 74.10)
MAP, PLGF 81.82 (70.39 to 90.24) 82.35 (56.57 to 96.20) 75.76 (57.74 to 88.91) 79.31 (70.80 to 86.27)
UTA-PI, PAPP-A 65.15 (52.42 to 76.47) 76.47 (50.10 to 93.19) 75.76 (57.74 to 88.91) 69.83 (60.61 to 78.00)
UTA-PI, PLGF 83.33 (72.13 to 91.38) 88.24 (63.56 to 98.54) 78.79 (61.09 to 91.02) 81.03 (72.71 to 87.72)
PLGF, PAPP-A 74.24 (61.99 to 84.22) 76.47 (50.10 to 93.19) 66.67 (48.17 to 82.04) 74.14 (65.18 to 81.82)
MAP, UTA-PI,
PAPP-A
77.27 (65.30 to 86.69) 88.24 (63.56 to 98.54) 87.88 (71.80 to 96.60) 82.76 (74.64 to 89.14)
MAP, PAPP-A,
PLGF
84.85 (73.90 to 92.49) 88.24 (63.56 to 98.54) 78.79 (61.09 to 91.02) 81.03 (72.71 to 87.72)
MAP, UTA-PI,
PLGF
87.88 (77.51 to 94.62) 94.12 (71.31 to 99.85) 90.91 (75.67 to 98.08) 89.66 (82.63 to 94.54)
UTA-PI, PAPP-A,
PLGF
84.85 (73.90 to 92.49) 88.24 (63.56 to 98.54) 78.79 (61.09 to 91.02) 81.03 (72.71 to 87.72)
MAP, UTA-PI,
PAPP-A, PLGF
87.88 (77.51 to 94.62) 94.12 (71.31 to 99.85) 90.91 (75.67 to 98.08) 89.66 (82.63 to 94.54)
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TABLE 12 Detection rate for pre-eclampsia at < 37 weeks’ gestation at a fixed SPR of 10%
Method of







Mat-CHs 45.89 (40.07 to 51.79) 40.68 (28.07 to 54.25) 41.55 (33.35 to 50.11) 44.83 (40.38 to 49.34)
MAP 54.45 (48.55 to 60.26) 44.07 (31.16 to 57.60) 47.18 (38.76 to 55.73) 50.51 (46.00 to 55.01)
UTA-PI 56.51 (50.61 to 62.27) 61.02 (47.44 to 73.45) 61.97 (53.45 to 69.98) 58.42 (53.93 to 62.81)
PLGF 60.62 (54.76 to 66.26) 61.02 (47.44 to 73.45) 60.56 (52.02 to 68.65) 60.65 (56.18 to 64.99)
PAPP-A 47.60 (41.75 to 53.50) 45.76 (32.72 to 59.25) 45.77 (37.39 to 54.33) 48.48 (43.99 to 52.99)
MAP, UTA-PI 65.75 (60.00 to 71.18) 69.49 (56.13 to 80.81) 73.24 (65.17 to 80.32) 68.36 (64.05 to 72.44)
MAP, PAPP-A 57.53 (51.64 to 63.27) 49.15 (35.89 to 62.50) 53.52 (44.97 to 61.93) 55.78 (51.27 to 60.22)
MAP, PLGF 70.21 (64.60 to 75.39) 66.10 (52.61 to 77.92) 64.79 (56.34 to 72.61) 66.13 (61.76 to 70.30)
UTA-PI, PAPP-A 56.85 (50.95 to 62.61) 62.71 (49.15 to 74.96) 63.38 (54.89 to 71.30) 59.23 (54.75 to 63.60)
UTA-PI, PLGF 67.47 (61.76 to 72.81) 71.19 (57.92 to 82.24) 71.13 (62.93 to 78.42) 66.94 (62.59 to 71.08)
PLGF, PAPP-A 62.67 (56.85 to 68.24) 62.71 (49.15 to 74.96) 60.56 (52.02 to 68.65) 63.49 (59.07 to 67.75)
MAP, UTA-PI,
PAPP-A
65.07 (59.30 to 70.53) 67.80 (54.36 to 79.38) 75.35 (67.42 to 82.19) 68.15 (63.84 to 72.25)
MAP, PAPP-A,
PLGF
70.89 (65.31 to 76.04) 67.80 (54.36 to 79.38) 64.79 (56.34 to 72.61) 67.34 (63.01 to 71.47)
MAP, UTA-PI,
PLGF
73.97 (68.54 to 78.91) 74.58 (61.56 to 85.02) 80.28 (72.78 to 86.48) 74.85 (70.77 to 78.62)
UTA-PI, PAPP-A,
PLGF
68.15 (62.47 to 73.46) 71.19 (57.92 to 82.24) 69.01 (60.72 to 76.50) 68.15 (63.84 to 72.25)
MAP, UTA-PI,
PAPP-A, PLGF
73.29 (67.82 to 78.27) 76.27 (63.41 to 86.38) 79.58 (72.00 to 85.88) 74.85 (70.77 to 78.62)
TABLE 13 Detection rate for pre-eclampsia at ≥ 37 weeks’ gestation at a fixed SPR of 10%
Method of







Maternal factors 34.46 (31.10 to 37.95) 35.00 (28.05 to 42.45) 30.21 (25.31 to 35.47) 33.52 (30.93 to 36.18)
MAP 39.82 (36.33 to 43.38) 36.67 (29.62 to 44.16) 37.76 (32.52 to 43.23) 38.29 (35.62 to 41.02)
UtA-PI 37.47 (34.03 to 41.00) 33.33 (26.50 to 40.73) 32.02 (27.03 to 37.35) 35.16 (32.54 to 37.85)
PLGF 38.77 (35.31 to 42.33) 31.67 (24.95 to 39.00) 32.02 (27.03 to 37.35) 34.53 (31.93 to 37.21)
PAPP-A 37.60 (34.16 to 41.14) 35.00 (28.05 to 42.45) 30.21 (25.31 to 35.47) 35.24 (32.62 to 37.93)
MAP, UtA-PI 42.04 (38.51 to 45.62) 40.56 (33.31 to 48.11) 42.60 (37.21 to 48.12) 41.43 (38.71 to 44.18)
MAP, PAPP-A 40.21 (36.71 to 43.78) 40.00 (32.78 to 47.55) 37.46 (32.23 to 42.92) 39.08 (36.39 to 41.81)
MAP, PLGF 41.91 (38.38 to 45.49) 38.33 (31.20 to 45.86) 38.07 (32.81 to 43.54) 39.31 (36.62 to 42.05)
UtA-PI, PAPP-A 38.12 (34.67 to 41.67) 36.11 (29.10 to 43.59) 32.33 (27.31 to 37.66) 36.34 (33.69 to 39.04)
UtA-PI, PLGF 38.51 (35.05 to 42.06) 37.22 (30.15 to 44.73) 35.95 (30.78 to 41.38) 36.88 (34.23 to 39.60)
PLGF, PAPP-A 39.03 (35.56 to 42.59) 32.22 (25.46 to 39.58) 30.21 (25.31 to 35.47) 35.71 (33.08 to 38.41)
MAP, UtA-PI,
PAPP-A
41.91 (38.38 to 45.49) 40.56 (33.31 to 48.11) 41.39 (36.03 to 46.90) 40.56 (37.86 to 43.32)
continued
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sequentially improved by the addition of one, two and three biomarkers; and (3) addition of PAPP-A to
any combination of biomarkers that includes PLGF has little benefit.
Our analysis uses two independent test data sets for assessment of screening performance: the ASPRE
SQS and the SPREE study. The AJOG data were used as a training data and their inclusion in the
analysis is questionable. However, this is a very large data set relative to the number of parameters
involved in model fitting. Moreover, the results from AJOG are very similar to those from the ASPRE
SQS and the SPREE study. For this reason, and to provide evidence based on large number of cases, we
decided to include the AJOG data.
TABLE 13 Detection rate for pre-eclampsia at ≥ 37 weeks’ gestation at a fixed SPR of 10% (continued )
Method of









41.91 (38.38 to 45.49) 37.22 (30.15 to 44.73) 36.25 (31.07 to 41.69) 39.31 (36.62 to 42.05)
MAP, UtA-PI,
PLGF
42.17 (38.64 to 45.75) 40.56 (33.31 to 48.11) 42.90 (37.50 to 48.43) 40.96 (38.24 to 43.71)
UtA-PI, PAPP-A,
PLGF
38.77 (35.31 to 42.33) 35.56 (28.58 to 43.02) 35.05 (29.91 to 40.45) 36.88 (34.23 to 39.60)
MAP, UtA-PI,
PAPP-A, PLGF
41.64 (38.13 to 45.23) 39.44 (32.25 to 46.99) 42.90 (37.50 to 48.43) 41.35 (38.63 to 44.1)
TABLE 14 Detection rate of all pre-eclampsia at a fixed SPR of 10%
Method of







Mat-CHs 37.62 (34.69 to 40.62) 36.40 (30.30 to 42.85) 33.62 (29.37 to 38.07) 36.67 (34.42 to 38.96)
MAP 43.86 (40.84 to 46.91) 38.49 (32.29 to 44.98) 40.59 (36.13 to 45.17) 41.69 (39.39 to 44.03)
UTA-PI 42.72 (39.72 to 45.77) 40.17 (33.90 to 46.68) 41.01 (36.54 to 45.60) 41.64 (39.33 to 43.98)
PLGF 44.80 (41.78 to 47.86) 38.91 (32.69 to 45.41) 40.59 (36.13 to 45.17) 41.81 (39.50 to 44.15)
PAPP-A 40.36 (37.39 to 43.39) 37.66 (31.49 to 44.13) 34.88 (30.59 to 39.37) 38.93 (36.65 to 41.24)
MAP, UTA-PI 48.58 (45.53 to 51.64) 47.70 (41.22 to 54.23) 51.80 (47.19 to 56.38) 48.93 (46.57 to 51.28)
MAP, PAPP-A 44.99 (41.96 to 48.05) 42.26 (35.92 to 48.79) 42.28 (37.79 to 46.88) 43.73 (41.40 to 46.08)
MAP, PLGF 49.72 (46.66 to 52.77) 45.19 (38.76 to 51.73) 46.09 (41.53 to 50.70) 46.78 (44.43 to 49.14)
UTA-PI, PAPP-A 43.29 (40.28 to 46.34) 42.68 (36.32 to 49.22) 41.65 (37.17 to 46.24) 42.71 (40.39 to 45.06)
UTA-PI, PLGF 46.50 (43.46 to 49.56) 45.61 (39.17 to 52.15) 46.51 (41.94 to 51.12) 45.25 (42.92 to 47.61)
PLGF, PAPP-A 45.56 (42.53 to 48.61) 39.75 (33.50 to 46.26) 39.32 (34.89 to 43.89) 43.45 (41.12 to 45.79)
MAP, UTA-PI,
PAPP-A
48.30 (45.25 to 51.36) 47.28 (40.81 to 53.82) 51.59 (46.98 to 56.17) 48.25 (45.90 to 50.61)
MAP, PAPP-A,
PLGF
49.91 (46.85 to 52.96) 44.77 (38.36 to 51.31) 44.82 (40.28 to 49.43) 47.12 (44.77 to 49.48)
MAP, UTA-PI,
PLGF
50.95 (47.89 to 54.00) 48.95 (42.45 to 55.48) 54.12 (49.51 to 58.68) 50.40 (48.04 to 52.75)
UTA-PI, PAPP-A,
PLGF
46.88 (43.84 to 49.94) 44.35 (37.95 to 50.90) 45.24 (40.69 to 49.85) 45.59 (43.25 to 47.95)
MAP, UTA-PI,
PAPP-A, PLGF
50.38 (47.32 to 53.43) 48.54 (42.04 to 55.06) 53.91 (49.30 to 58.47) 50.68 (48.32 to 53.03)
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Chapter 9 Competing risk model:
two-stage screening
Sections of this chapter have been reprinted from Am J Obstet Gynecol, 220/2, Wright A, Wright D,Syngelaki A, Georgantis A, Nicolaides KH, Two-stage screening for preterm preeclampsia at
11–13 weeks’ gestation, 197.e1–197.e11, 2019, with permission from Elsevier50 and Am J Obstet Gynecol,
220/2, Wright D, Tan MY, O’Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides KH, Predictive
performance of the competing risk model in screening for preeclampsia, 199.e1–199.e13, 2019,
with permission from Elsevier.35
This chapter shows an application of competing risk model in which risks are updated as new information
becomes available.50 In this application, a first-stage assessment using Mat-CHs alone or a combination of
Mat-CHs with a subset of the biomarkers (i.e. MAP, UTA-PI and PLGF) is applied to the whole population.
Based on the risks from this first-stage assessment, the population is stratified into subpopulations. One
with risks below a predetermined level who are classified as screen negative and those with risks above
that level for measurements of the remaining markers. After this second stage of measurement, the risks
are updated and then the subpopulation is stratified into high- and low-risk strata (Figure 17).
The rationale for this two-stage stratification process is to achieve performance close to that of the
full test with all three markers, but restricting the need for measurement of some of the markers to
a subset of the population. Depending on the setting, the choice of markers measured at each stage




We used the data from AJOG, ASPRE SQS and the SPREE study on a combined total of 61,174 singleton




Screen negative Screen positive
Screen positiveScreen negative
Second-stage screening
FIGURE 17 Two-stage screening for preterm pre-eclampsia.
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Women with a singleton pregnancy who were undergoing first-trimester combined screening for
pre-eclampsia and who subsequently delivered a morphologically normal live or stillborn infant
at ≥ 24 weeks’ gestation were included. We excluded pregnancies with aneuploidies and major fetal
abnormalities and those ending in termination, miscarriage or fetal death at < 24 weeks’ gestation.
Statistical analysis
Patient-specific risks of delivery with pre-eclampsia at < 32 and < 37 weeks’ gestation were calculated
using the competing risks model to combine the prior distribution of the gestational age at delivery
with pre-eclampsia, obtained from Mat-CHs and medical history, with various combinations of MoM
values of MAP, UTA-PI and PLGF.
We estimated the DR of preterm pre-eclampsia and early pre-eclampsia at an overall SPR of 10% and
20% from a policy in which first-stage screening of the whole population is carried out by some of the
components of the triple test and second-stage screening by the full triple test on women selected on
the basis of results from first-stage screening.
The risk of development of pre-eclampsia is higher in women of black or South Asian racial origin than
in white women.33 Consequently, in screening a population of mixed racial origins for a given risk
cut-off point the DR and SPR would be higher in black and South Asian women than in white women
and the overall performance would be dependent on the proportion of the various racial groups within
that population. The majority of our patients were white (44,684/61,174) and, therefore, we decided to
develop a model based on white women and then observe the performance of screening at fixed-risk
cut-off points in different racial groups. The following steps were used to develop the model. First,
Mat-CHs and medical history from the 44,684 records were sampled with replacement 1,000,000 times.
For each record, the prior distribution of time to delivery was obtained from the competing risk model.33
Second, the MoM values of MAP, UTA-PI and PLGF were simulated from the fitted multivariate Gaussian
distribution for log-transformed MoM values.17 Third, posterior distributions of times to delivery with
pre-eclampsia were obtained by combining the prior distribution of gestational age at delivery with
pre-eclampsia33 and the likelihoods of the biomarkers using Bayes’ theorem. Risks of pre-eclampsia
were obtained by calculating the area under the posterior distribution.
The performance of screening for pre-eclampsia was assessed via a two-stage strategy (see Figure 16).
On the basis of the results of first-stage screening, the population was divided into a low-risk screen-
negative group and a higher-risk group in need of further testing. After such testing, the patients
were again classified as screen negative or screen positive. The performance of three first-stage
strategies was examined: screening of the whole population by Mat-CHs alone; Mat-CHs, MAP and
UTA-PI; and Mat-CHs, MAP and PLGF. The second-stage test was the triple test. The proportion of
women continuing to the second stage and the overall SPR and DR for preterm pre-eclampsia and
early pre-eclampsia were defined by various stage 1 and 2 risk cut-off points. Risk cut-off points were
selected so that the DR of preterm pre-eclampsia was within 1% of that achieved by screening the
whole population with the triple test.
Results
Model-based performance of two-stage screening
The model-based DR of preterm pre-eclampsia and early pre-eclampsia in women of white racial origin
at a SPR of 10% and 20% is shown in Tables 15 and 16. When screening the whole population by the
triple test at a SPR of 10%, the DR of preterm pre-eclampsia was 67% and of early pre-eclampsia was
85%. The corresponding values at a SPR of 20% were 81% and 93%, respectively.
In two-stage screening with Mat-CHs as the method of screening in the first stage and reserving
measurements of MAP, UTA-PI and PLGF for the second stage to only 70% of the population, a similar
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TABLE 15 Empirical and model-based performance of two-stage screening at 11–13 weeks’ gestation for pre-eclampsia
with delivery at < 32 and < 37 weeks’ gestation at a fixed overall SPR of 10% for white women in the population













Mat-CHs White (n = 25,879) 72.3 12.3 (11.9 to 12.7) 66.9 (58.4 to 74.6) 81.0 (58.1 to 94.6)
Black (n= 6681) 99 36.6 (35.5 to 37.8) 92.7 (86.6 to 96.6) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
88.7 21.3 (19.3 to 23.4) 95.0 (75.1 to 99.9) 100.0 (54.1 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 25,879) 36.7 12.2 (11.8 to 12.6) 67.6 (59.2 to 75.3) 81.0 (58.1 to 94.6)
Black (n= 6681) 70.5 36.2 (35.0 to 37.3) 92.7 (86.6 to 96.6) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
50.6 20.8 (18.9 to 22.9) 95.0 (75.1 to 99.9) 100.0 (54.1 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 25,879) 25.2 12.2 (11.8 to 12.6) 67.6 (59.2 to 75.3) 85.7 (63.7 to 97.0)
Black (n= 6681) 56.8 36.4 (35.2 to 37.6) 92.7 (86.6 to 96.6) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
36.8 21.0 (19.1 to 23.1) 95 (75.1 to 99.9) 100.0 (54.1 to 100.0)
ASPRE SQS
Mat-CHs White (n = 6883) 70.6 7.7 (7.1 to 8.4) 65.8 (48.6 to 80.4) 100.0 (63.1 to 100.0)
Black (n= 1090) 98.1 28.6 (26 to 31.4) 92.9 (66.1 to 99.8) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
86.8 10.8 (8.1 to 14) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 6883) 33 7.7 (7.0 to 8.3) 65.8 (48.6 to 80.4) 100.0 (63.1 to 100.0)
Black (n= 1090) 67.9 28.6 (26 to 31.4) 92.9 (66.1 to 99.8) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
42.9 10.8 (8.1 to 14) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 6883) 17.2 7.7 (7.1 to 8.4) 63.2 (46 to 78.2) 87.5 (47.3 to 99.7)
Black (n= 1090) 49.3 28.6 (26.0 to 31.4) 92.9 (66.1 to 99.8) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
23.6 10.6 (7.9 to 13.8) 100.0 (29.2 to 100.0)
SPREE study
Mat-CHs White (n = 11,922) 69.8 7.0 (6.6 to 7.5) 69.6 (58.2 to 79.5) 78.9 (54.4 to 93.9)
Black (n= 2337) 98.6 28.8 (26.9 to 30.6) 91.3 (79.2 to 97.6) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
87.6 12.8 (11.1 to 14.7) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 11,922) 31.5 7.0 (6.5 to 7.4) 72.2 (60.9 to 81.7) 84.2 (60.4 to 96.6)
Black (n= 2337) 64.4 28.3 (26.5 to 30.2) 91.3 (79.2 to 97.6) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
45.5 12.5 (10.8 to 14.4) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 11,922) 16.2 6.9 (6.5 to 7.4) 68.4 (56.9 to 78.4) 84.2 (60.4 to 96.6)
Black (n= 2337) 49.8 28.5 (26.7 to 30.4) 89.1 (76.4 to 96.4) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
24.8 12.6 (10.8 to 14.4) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
DOI: 10.3310/eme07080 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 8
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Poon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
55
TABLE 16 Empirical and model-based performance of two-stage screening at 11–13 weeks’ gestation for pre-eclampsia
with delivery at < 32 and < 37 weeks’ gestation at a fixed overall SPR of 20% for white women in the population













Mat-CHs White (n = 25,879) 72.3 22.6 (22.0 to 23.1) 79.9 (72.2 to 86.2) 90.5 (69.6 to 98.8)
Black (n= 6681) 99.0 53.2 (52.0 to 54.4) 98.4 (94.2 to 99.8) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
88.7 34.7 (32.4 to 37.1) 95.0 (75.1 to 99.9) 100.0 (54.1 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 25,879) 44.6 22.4 (21.9 to 22.9) 81.3 (73.8 to 87.4) 95.2 (76.2 to 99.9)
Black (n= 6681) 77.2 52.3 (51.1 to 53.5) 97.6 (93.0 to 99.5) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
57.9 33.9 (31.6 to 36.2) 95.0 (75.1 to 99.9) 100.0 (54.1 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 25,879) 34.7 22.3 (21.7 to 22.8) 79.9 (72.2 to 86.2) 90.5 (69.6 to 98.8)
Black (n= 6681) 67.0 52.3 (51.1 to 53.5) 97.6 (93 to 99.5) 100.0 (90.5 to 100.0)
South Asian
(n= 1623)
46.6 33.6 (31.3 to 36) 95 (75.1 to 99.9) 100.0 (54.1 to 100.0)
ASPRE SQS
Mat-CHs White (n = 6883) 70.6 16.1 (15.3 to 17) 78.9 (62.7 to 90.4) 100.0 (63.1 to 100.0)
Black (n= 1090) 98.1 45 (42.1 to 48.1) 100.0 (76.8 to 100.0) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
86.8 22.1 (18.4 to 26.1) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 6883) 40.6 16.2 (15.4 to 17.1) 84.2 (68.7 to 94) 100.0 (63.1 to 100.0)
Black (n= 1090) 74.7 44.5 (41.5 to 47.5) 100.0 (76.8 to 100.0) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
52.2 22.3 (18.6 to 26.4) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 6883) 25.5 15.8 (15 to 16.7) 81.6 (65.7 to 92.3) 100.0 (63.1 to 100.0)
Black (n= 1090) 57.7 44.6 (41.6 to 47.6) 100.0 (76.8 to 100.0) 100.0 (63.1 to 100.0)
South Asian
(n= 462)
35.3 21.4 (17.8 to 25.5) 100.0 (29.2 to 100.0)
SPREE study
Mat-CHs White (n = 11,922) 69.8 14.9 (14.3 to 15.6) 82.3 (72.1 to 90.0) 84.2 (60.4 to 96.6)
Black (n= 2337) 98.6 44.6 (42.6 to 46.7) 97.8 (88.5 to 99.9) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
87.6 23.6 (21.4 to 25.9) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP +UTA-PI
White (n = 11,922) 38.4 14.7 (14.1 to 15.4) 84.8 (75.0 to 91.9) 89.5 (66.9 to 98.7)
Black (n= 2337) 72.5 43.9 (41.8 to 45.9) 97.8 (88.5 to 99.9) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
55.8 23.6 (21.4 to 25.9) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
Mat-CHs +
MAP + PLGF
White (n = 11,922) 23.8 14.4 (13.8 to 15) 83.5 (73.5 to 90.9) 84.2 (60.4 to 96.6)
Black (n= 2337) 60.2 43.9 (41.9 to 46) 95.7 (85.2 to 99.5) 100.0 (71.5 to 100.0)
South Asian
(n= 1361)
34.8 22.9 (20.7 to 25.3) 100.0 (78.2 to 100.0) 100.0 (29.2 to 100.0)
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DR was achieved as when screening the whole population by the triple test, irrespective of whether the
SPR was 10% or 20% (Figure 18). In the case of first-stage screening by Mat-CHs, MAP and UTA-PI,
the DR was similar to that achieved by screening the whole population with the triple test by limiting
measurement of PLGF in the second stage to approximately 30% of the population for an overall
SPR of 10% and 40% for a SPR of 20%. In the case of first-stage screening by Mat-CHs, MAP and
PLGF, a similar DR was achieved as in screening the whole population with the triple test by limiting
measurement of UTA-PI in the second stage to approximately 20% of the population for an overall SPR
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FIGURE 18 Relationship between model-based DR of pre-eclampsia with delivery at < 37 weeks’ gestation (dark blue
curve) and < 32 weeks’ gestation (light blue curve) and percentage of the population requiring second-stage screening at
a fixed overall SPR of 20% in women of white racial origin. Screening at first stage (a) Mat-CHs; (b) Mat-CHs, MAP and
UTA-PI; and (c) Mat-CHs, MAP and PLGF.
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Selection of risk cut-off points for first- and second-stage screening
On the basis of the model-based results we selected the following risk cut-off points for preterm
pre-eclampsia to assess the empirical performance of screening at an overall SPR of 10%. For the
first stage, the risk cut-off points for selecting the group in need of second-stage screening was 1 in
600 when screening was with Mat-CHs, 1 in 300 when screening using a combination of Mat-CHs,
MAP and UTA-PI, and 1 in 200 when screening or Mat-CHs, MAP and PLGF. The risk cut-off point for
selecting the screen-positive group after second-stage screening was 1 in 100.
On the basis of the model-based results we selected the following risk cut-off points for preterm
pre-eclampsia to assess the empirical performance of screening at an overall SPR of 20%. For the
first stage, the risk cut-off points for selecting the group in need of second-stage screening was 1 in
600 when screening was with Mat-CHs, 1 in 400 in screening using a combination of Mat-CHs, MAP
and UTA-PI, and 1 in 300 when screening or Mat-CHs, MAP and PLGF. The risk cut-off point for
selecting the screen-positive group after second-stage screening was 1 in 200.
Empirical performance of two-stage screening
Empirical performance of two-stage screening for white women in AJOG, ASPRE SQS and the SPREE
study at a fixed overall SPR of 10% and a fixed SPR of 20% is shown in Tables 15 and 16, respectively.
The results of the ASPRE SQS and the SPREE study are similar (with values within the 95% CIs) in
terms of the proportion of the population requiring second-stage screening, overall SPR and DR of
pre-eclampsia. In AJOG, the proportions of the population requiring second-stage screening and overall
SPR were higher than in the other two data sets. The likely explanation for this is that the prior risk
was higher in the AJOG data set than in the other two data sets.
In all three data sets, at the same risk cut-off points for first- and second-stage screening, among
women of black racial origin and women of South Asian racial origin both the proportion requiring
second-stage screening and the overall SPR and DR were considerably higher than among white women.
Discussion
The findings of this study demonstrate that a similar SPR and DR can be achieved with a two-stage
strategy of screening at substantially lower costs than with carrying out screening with all biomarkers
in the whole population. If the method of first-stage screening is Mat-CHs, then measurement of
biomarkers can be reserved for only 70% of the population and if some of the biomarkers are included
in first-stage screening then the need for the complete triple test can be reduced to 30–40% of the
population.
Screening by the triple test in a population of white women resulted in a DR of preterm pre-eclampsia
of 67% at a SPR of 10%, and this increased to 81% at a SPR of 20%. Randomised trials on the use of
aspirin have reported that the drug is not associated with increased risk of adverse events, and in
the case of antepartum haemorrhage the risk may actually be reduced.51 In this respect, it may be
acceptable that in screening for pre-eclampsia the SPR could be about 20% so as to maximise the DR.
The inevitable consequence of fixing a risk cut-off point aiming to achieve a given SPR in a white
population is that the rate would be considerably higher for women of black or South Asian racial origin.
An alternative strategy in screening is to fix the SPR to be the same for all racial groups and to use
different risk cut-off points for each group. However, in a multiracial society such strategy would not be
easy to implement, and in any case it would be wrong because it would merely mask the increased risk
for pre-eclampsia in certain racial groups. Inevitably, the overall performance of screening in a racially
mixed population will depend on the proportion of the various racial groups. This is analogous to screening
for Down syndrome, for which the maternal age-derived prior risk is combined with the measurement of
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first- and/or second-trimester biomarkers to derive the posterior risk. At a fixed-risk cut-off point both the
SPR and the DR increase with maternal age and, therefore, the overall performance of screening depends
of the maternal age distribution of a given study population.
The strengths of this screening study are the (1) large number of patients examined; (2) accurate
recording of maternal factors and biomarkers; (3) use of Bayes’ theorem to combine the prior distribution
of gestational age at delivery with pre-eclampsia from maternal factors with biomarkers to estimate
patient-specific risks and the performance of screening for pre-eclampsia delivering at different stages of
pregnancy; and (4) comparison of model-based results and empirical results on performance of screening.
The observed performance of two-stage screening applies to our study population and comparison
between studies requires the appropriate adjustments for the characteristics of the population under
investigation. In the application of screening in different countries it is likely that adjustments would
be necessary for the calculation of MoM values for the biomarkers and establishment of a system for
quality assurance of the measurements.
DOI: 10.3310/eme07080 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 8
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Poon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
59

Chapter 10 Competing risks model:
incorporating a new biomarker
Our approach to screening for pre-eclampsia is to use Bayes’ theorem to combine the prior distributionof the gestational age at delivery with pre-eclampsia, obtained from Mat-CHs and medical history,
with the results of various combinations of biophysical and biochemical measurements.17,33 A major
advantage of this approach is that the model can easily be updated with new biomarkers.
The three biomarkers found to be useful in first-trimester screening for pre-eclampsia are MAP, UTA-PI
and PLGF.17 This chapter explores the potential value of another biomarker, inhibin A. Inhibin A is a
glycoprotein hormone that is mainly produced by the placenta.52 In patients with established pre-eclampsia
there is an up to 10-fold increase in the maternal circulating levels of inhibin A and there is also evidence




We conducted a case–control study drawn from a large prospective screening study for adverse
obstetric outcomes in women attending for their routine visit at 11+0 to 13+6 weeks’ gestation,
which included recording of maternal demographic characteristics and medical history, and
measurement of MAP, UTA-PI and PLGF. Inhibin A concentration was measured by a fully automated
biochemical analyser in stored serum samples from 98 women who subsequently developed
pre-eclampsia and 200 women (controls) who did not develop any hypertensive disorder of pregnancy.
Each case of pre-eclampsia was matched with two women (controls) who had blood collected on
the same day.
The MoM values for inhibin A were calculated from a linear regression model fitted to log10 inhibin A
concentrations, with various Mat-CHs and previous medical and pregnancy history as predictors.
Backwards elimination was used for variable selection. To determine whether or not inhibin A would
be useful in predicting pre-eclampsia, terms for pre-eclampsia and the gestational age at delivery with
pre-eclampsia were included in the model. The partial residuals after excluding the contribution of
pre-eclampsia comprised the log10 MoM values. Plots of log10 inhibin A MoM compared with log10 MAP,
UTA-PI and PLGF MoM values were produced to explore correlations between markers and the
behaviour between marker profiles in pre-eclampsia pregnancies. The standard deviations of log10
inhibin A MoM values were also estimated. The competing risks model was used to calculate risks for
various combinations of biomarkers so that the performance of screening could be assessed based on
the inclusion of inhibin A.
Model-based estimates of screening performance were obtained via multiple imputation. The data for
our previous study on prospective non-intervention screening for pre-eclampsia by a combination of
Mat-CHs, MAP, UTA-PI and PLGF at 11+0 to 13+6 weeks’ gestation in 61,174 singleton pregnancies,
including 1770 (2.9%) women who developed pre-eclampsia,57 were sampled, with replacement, to create
a new data set consisting of 100,000 records. Based on parameters obtained from the case–control study,
as outlined above, inhibin A MoM values were simulated for these 100,000 records. Risks were calculated
for various combinations of the four biomarkers and screening performance was assessed in terms of
DR and FPR. This process was repeated 10 times and DRs and FPRs were summarised.
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Screening study
Serum inhibin A was measured in all 5245 stored samples from patients who participated in the SPREE
study at King’s College Hospital. These included 140 patients who developed pre-eclampsia. The competing
risk model was used to calculate risks for various combinations of biomarkers so that the performance of
screening could be assessed based on the inclusion of inhibin A.
Results
Case–control study
In women who developed pre-eclampsia, compared with those without pre-eclampsia, the MoM values
of inhibin A (Figure 19), UTA-PI and MAP were increased and PLGF was decreased, and the deviation
from normal was greater for early pre-eclampsia than for late pre-eclampsia for all four biomarkers.
The empirical and model-based performance of screening for pre-eclampsia by maternal factors
with combinations of biomarkers is shown in Table 17. Addition of inhibin A was associated with a
non-significant improvement in the performance of screening by (1) Mat-CHs and PLGF, (2) Mat-CHs,
MAP and PLGF and (3) Mat-CHs, MAP, UTA-PI and PLGF. The empirical results were comparable to
the model-based results. However, in view of the small number of cases examined and the wide CIs,
there is considerable uncertainty concerning the additional value of inhibin A in improving the
performance of screening achieved by the other biomarkers.
It was concluded that inclusion of serum inhibin A could potentially improve the performance of
first-trimester screening for pre-eclampsia, but this needs to be investigated further by prospective
screening studies.
26 28 30 32 34 36 38 40 42




















FIGURE 19 Scatter diagram and regression line for the relationship between inhibin A MoM values and gestational age
at delivery in pregnancies with pre-eclampsia.
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Screening study
The DR of all pre-eclampsia and pre-eclampsia with delivery at < 37 and < 32 weeks’ gestation is
shown in Table 18. Although inhibin A improved the prediction provided by maternal factors alone, it
did not improve the prediction provided by biomarkers that included PLGF. The findings suggest that
although inhibin A is a biomarker of pre-eclampsia, it is unlikely to improve the prediction provided by
a combination of MAP and PLGF or MAP, UTA-PI and PLGF.
TABLE 17 Empirical (with 95% CI) and model-based DRs at a 10% FPR in screening for pre-eclampsia with delivery at
< 37 and < 32 weeks’ gestation by maternal factors and combinations of biomarkers
Method of screening
Pre-eclampsia with delivery at
< 37 weeks’ gestation
Pre-eclampsia with delivery at
< 32 weeks’ gestation
Empirical (95% CI) Modelled Empirical (95% CI) Modelled
Mat-CHs 38.3 (24.5 to 53.6) 46.6 33.3 (7.5 to 70.1) 52.6
Mat-CHs + PLGF 46.8 (32.1 to 61.9) 64.2 66.7 (29.9 to 92.5) 74.1
Mat-CHs + inhibin A 46.8 (32.1 to 61.9) 52.1 66.7 (29.9 to 92.5) 64.1
Mat-CHs + PLGF+ inhibin A 55.3 (40.1 to 69.8) 67.1 77.8 (40.0 to 97.2) 80.9
Mat-CHs +MAP 46.8 (32.1 to 61.9) 53.4 66.7 (29.9 to 92.5) 65.5
Mat-CHs +MAP +UTA-PI 70.2 (55.1 to 82.7) 69.6 88.9 (51.8 to 99.7) 83.6
Mat-CHs +MAP + PLGF 59.6 (44.3 to 73.6) 68.8 66.7 (29.9 to 92.5) 81.9
Mat-CHs +MAP + inhibin A 55.3 (40.1 to 69.8) 59.2 77.8 (40.0 to 97.2) 74.1
Mat-CHs +MAP + PLGF+ inhibin A 68.1 (52.9 to 80.9) 72.1 77.8 (40.0 to 97.2) 85.8
Mat-CHs +MAPUTA-PI+ PLGF 74.5 (59.7 to 86.1) 76.7 88.9 (51.8 to 99.7) 90.5
Mat-CHs +MAP +UTA-PI+
PLGF + inhibin A
72.3 (57.4 to 84.4) 77.8 88.9 (51.8 to 99.7) 92.8








< 37 weeks’ gestation
Pre-eclampsia
with delivery at
< 32 weeks’ gestation
Mat-CHs 37 (29 to 46) 49 (34 to 64) 60 (26 to 88)
Mat-CHs + inhibin A 41 (32 to 49) 60 (44 to 74) 80 (44 to 97)
Mat-CHs + PLGF 48 (39 to 56) 60 (44 to 74) 80 (44 to 97)
Mat-CHs + PLGF+ inhibin A 48 (39 to 56) 64 (49 to 78) 80 (44 to 97)
Mat-CHs +MAP + PLGF 54 (45 to 62) 67 (51 to 80) 80 (44 to 97)
Mat-CHs +MAP + PLGF+ inhibin A 51 (42 to 59) 67 (51 to 80) 70 (35 to 93)
Mat-CHs +MAP +UTA-PI+ PLGF 61 (52 to 69) 80 (65 to 90) 100 (69 to 100)
Mat-CHs +MAP +UTA-PI+ PLGF+ inhibin A 61 (52 to 69) 80 (65 to 90) 100 (69 to 100)
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Discussion
This study has demonstrated the feasibility of utilising the competing risk model to investigate the
potential value of new biomarkers of pre-eclampsia.
The findings of the case–control study demonstrated that in women who developed pre-eclampsia,
inhibin A is increased and the deviation from normal is greater for early pre-eclampsia than late
pre-eclampsia. On the basis of modelling, it was suggested that addition of inhibin A may improve the
performance of screening by Mat-CHs and combinations of MAP, UTA-PI and PLGF. Although the
empirical results were compatible with the model-based results, there was considerable uncertainty
concerning the additional value of inhibin A in improving the performance of screening achieved by
the other biomarkers. The results of the screening demonstrated that inhibin A is unlikely to be a
useful first trimester biomarker of pre-eclampsia.
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Chapter 11 Competing risks model:
prediction of small for gestational
age neonates
Small for gestational age neonates can be constitutionally small or growth can be restricted because ofimpaired placentation, fetal abnormalities or congenital infection. In pre-eclampsia, especially early
and preterm pre-eclampsia, many fetuses are SGA.58 Additionally, preterm SGA in the absence of pre-
eclampsia is associated with similar maternal factors and biomarker profile as in preterm pre-eclampsia.59
It could therefore be anticipated that first-trimester combined screening for preterm pre-eclampsia would
also identify a high proportion of SGA neonates in both the presence and the absence of pre-eclampsia.
In this chapter we use the data from the SPREE study38 to examine the effect of first-trimester
screening for pre-eclampsia on the prediction of SGA neonates.60
Methods
The data for this study were derived from the SPREE study.38 We investigated the performance of
screening for SGA by a combination of Mat-CHs and biomarkers at 11–13 weeks’ gestation. In the
ASPRE trial, women with singleton pregnancies identified by combined screening as being at high risk
for preterm pre-eclampsia (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11 to
14 weeks’ gestation until 36 weeks’ gestation) compared with placebo.40 We used the data from
the SPREE study to estimate the proportion of SGA neonates born at ≥ 37, < 37 and < 32 weeks’
gestation, with first-trimester combined risk for preterm pre-eclampsia (calculated by the competing
risk model through a combination of Mat-CHs, MAP, UTA-PI and PLGF) of > 1 in 100.17,33
Data on pregnancy outcome were collected from the hospital maternity records or the women’s
general medical practitioners. The diagnosis of SGA < 10th, < 5th or < 3rd percentile was based on a
reference range of birthweight with gestational age in our population.61 The pregnancies with SGA
fetuses were subdivided according to the presence or absence of pre-eclampsia.21,34
Results
First-trimester screening was carried out in 17,051 pregnancies, but 304 were lost to follow-up and
296 resulted in miscarriage or pregnancy termination at < 24 weeks’ gestation. Therefore, the study
population comprised 16,451 pregnancies.60
Pre-eclampsia developed in 473 (2.9%) pregnancies, including 33 with early pre-eclampsia, 142 with preterm
pre-eclampsia and 331 with term pre-eclampsia (Table 19). In the early pre-eclampsia group, 84.8%,
84.8% and 81.8% of babies were SGA < 10th, < 5th and < 3rd percentile, respectively. In the preterm




< 10th percentile < 5th percentile < 3rd percentile
< 32 weeks’ gestation 33 28 (84.8) 28 (84.8) 27 (81.8)
< 37 weeks’ gestation 142 100 (70.4% 86 (60.6) 78 (54.9)
≥ 37 weeks’ gestation 331 64 (19.3) 46 (13.9) 38 (11.5)
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pre-eclampsia group, 70.4%, 60.6% and 54.9% of babies were SGA < 10th, < 5th and < 3rd percentile,
respectively. In the term pre-eclampsia group, 19.3%, 13.9% and 11.5% of babies were SGA < 10th, < 5th
and < 3rd percentile, respectively.60
Birth at < 32, < 37 and ≥ 37 weeks’ gestation occurred in 172 (1.0%), 950 (5.8%) and 15,501 (94.2%)
pregnancies, respectively. The proportion of babies who were SGA and the contribution of pre-eclampsia
to the incidence of SGA are shown in Table 20. Essentially, 41.3% of babies born at < 32 weeks were SGA
< 10th percentile and in 39.4% of such pregnancies there was pre-eclampsia. Similarly, a high proportion
of babies born at < 37 weeks were SGA < 10th percentile (36.1%) and in 29.2% of such pregnancies there
was pre-eclampsia. In contrast, the incidence of SGA < 10th in babies born at term was 11.4%, and only
3.6% of these babies were from pregnancies with pre-eclampsia.60
In screening by a combination of Mat-CHs, MAP, UTA-PI and PLGF and a risk cut-off point for
preterm pre-eclampsia of 1 in 100, the SPR was 12.2% (2014/16,451) and the high-risk group included
30 (90.9%) of early pre-eclampsia, 118 (83.1%) of preterm pre-eclampsia and 162 (48.9%) of term
pre-eclampsia. The proportion of SGA neonates from all pregnancies and those with and without
pre-eclampsia with a first-trimester combined risk for preterm pre-eclampsia of > 1 in 100 is shown
in Table 21.60
In the high-risk group, the proportions of neonates born at ≥ 37 weeks' gestation who were below the
10th, 5th and 3rd weight percentile were 20.7%, 25.2% and 26.0%, respectively. The corresponding
percentages for those born at < 37 weeks’ gestation were 45.8%, 48.9% and 51.8% and for those
born at < 32 weeks’ gestation were 56.3%, 60.0% and 63.2%. In the group of SGA < 10th percentile
neonates from pregnancies with pre-eclampsia, the high-risk group included about 81% of those born
at < 37 weeks’ gestation and 89% of those born at < 32 weeks’ gestation. The corresponding values
from pregnancies without pre-eclampsia were approximately 31% and 35%. In the group of SGA < 5th
percentile neonates from pregnancies with pre-eclampsia, the high-risk group included about 79% of
those born at < 37 weeks’ gestation and 89% of those born at < 32 weeks’ gestation. The corresponding
values from pregnancies without pre-eclampsia were approximately 34% and 38%. In the group of SGA
< 3rd percentile neonates from pregnancies with pre-eclampsia, the high-risk group included about 78% of
those born at < 37 weeks’ gestation and 89% of those born at < 32 weeks’ gestation. The corresponding
values from pregnancies without pre-eclampsia were approximately 38% and 40%.60
TABLE 20 Proportion of SGA neonates and the contribution of pre-eclampsia in their incidence in the SPREE study




≥ 37 weeks’ gestation 15,501 1761 (11.4) 64 (3.6)
< 37 weeks’ gestation 950 343 (36.1) 100 (29.2)
< 32 weeks’ gestation 172 71 (41.3) 28 (39.4)
< 5th percentile
≥ 37 weeks’ gestation 15,501 988 (6.4) 46 (4.7)
< 37 weeks’ gestation 950 266 (28.0) 86 (32.3)
< 32 weeks’ gestation 172 66 (38.4) 28 (42.4)
< 3rd percentile
≥ 37 weeks’ gestation 15,501 684 (4.4) 38 (5.6)
< 37 weeks’ gestation 950 226 (23.8) 78 (34.5)
< 32 weeks’ gestation 172 57 (33.1) 27 (47.4)
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Discussion
The findings of this study demonstrate that (1) neonates are SGA < 10th percentile in 70% of
pregnancies with preterm pre-eclampsia and in 85% of those with early pre-eclampsia; (2) in women
who deliver preterm and early SGA neonates there is pre-eclampsia in 29% and 39% of cases,
respectively; and (3) screening for preterm pre-eclampsia by a combination of Mat-CHs, MAP, UTA-PI
and PLGF at 11–13 weeks’ gestation identifies a high-risk group that contains about 46% of cases of
preterm SGA and 56% of cases of early SGA.
Analysis of data from the SPREE study and the ASPRE trial showed that in pregnancies identified by
first-trimester combined screening as being at high-risk for preterm pre-eclampsia, use of aspirin reduces
the incidence of preterm SGA by about 40% and that of early SGA by 73%.60 The aspirin-related decrease
in incidence of SGA was mainly due to a decrease in the pregnancies with pre-eclampsia, the decrease
being approximately 70% in babies born at < 37 weeks’ gestation and approximately 90% in babies born
at < 32 weeks’ gestation. In the pregnancies without pre-eclampsia use of aspirin was not associated with
a significant reduction in incidence of SGA. On the basis of these results, it was estimated that first-trimester
screening for preterm pre-eclampsia and use of aspirin in the high-risk group would potentially reduce the
incidence of preterm and early SGA by about 20% and 40%, respectively.60
Preterm pre-eclampsia is, to a great extent, predictable by first-trimester combined screening and
preventable by use of aspirin (i.e. 150 mg/day from the first to the third trimester).7,17,33 A beneficial
consequence of such strategy is the prevention of a high proportion of cases of preterm SGA, because
(1) preterm pre-eclampsia is commonly associated with SGA and (2) a high proportion of cases of
preterm SGA are associated with pre-eclampsia.
The ASPRE trial demonstrated that, in women identified by means of first-trimester screening as being
at high risk for pre-eclampsia, use of aspirin reduces the incidence of preterm pre-eclampsia and
early pre-eclampsia by approximately 60% and 90%, respectively.7 A secondary analysis of the trial
TABLE 21 Proportion of SGA neonates from all pregnancies and those with and without pre-eclampsia with a first
trimester combined risk for preterm pre-eclampsia of > 1 in 100
Birth weight
SGA all pregnancies SGA with pre-eclampsia SGA no pre-eclampsia
All, n
Pre-eclampsia risk
> 1 in 100, n (%) All, n
Pre-eclampsia risk
> 1 in 100, n (%) All, n
Pre-eclampsia risk
> 1 in 100, n (%)
< 10th percentile
≥ 37 weeks’ gestation 1761 365 (20.7) 64 38 (59.4) 1697 327 (19.3)
< 37 weeks’ gestation 343 157 (45.8) 100 81 (81.0) 243 76 (31.3)
< 32 weeks’ gestation 71 40 (56.3) 28 25 (89.3) 43 15 (34.9)
< 5th percentile
≥ 37 weeks’ gestation 988 249 (25.2) 46 31 (67.4) 942 218 (23.1)
< 37 weeks’ gestation 266 130 (48.9) 86 68 (79.1) 180 62 (34.4)
< 32 weeks’ gestation 65 39 (60.0) 28 25 (89.3) 37 14 (37.8)
< 3rd percentile
≥ 37 weeks’ gestation 684 178 (26.0) 38 27 (71.1) 646 151 (23.4)
< 37 weeks’ gestation 226 117 (51.8) 78 61 (78.2) 148 56 (37.8)
< 32 weeks’ gestation 57 36 (63.2) 27 24 (88.9) 30 12 (40.0)
DOI: 10.3310/eme07080 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 8
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Poon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
67
demonstrated that use of aspirin reduces the length of stay in the neonatal intensive care unit by
approximately 70%.62 More than 80% of the length of stay was contributed from babies born at
< 32 weeks’ gestation and the aspirin-related reduction in length of stay could essentially be attributed
to prevention of early pre-eclampsia. The consequence of reduction in length of stay in the neonatal
intensive care unit is a substantial saving in health-care cost, which is well in excess of the cost of
population screening and treatment of the high-risk group with aspirin. Reduction in the risk of birth
at < 32 weeks’ gestation is also likely to be associated with reduction in risk of infant death, cerebral
palsy and long-term use of specialised health-care resources.63–65
In conclusion, first-trimester screening for pre-eclampsia by the combined test identifies a high
proportion of cases of preterm SGA that can potentially be prevented by the prophylactic use of
aspirin. Most cases of SGA, particularly those delivering at term, are neither predictable in the
first trimester nor preventable by prophylactic use of aspirin.
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Appendix 1 The competing risk model
The competing risks model18,33 for pre-eclampsia is a model for the distribution of gestational age,g (weeks), at delivery with pre-eclampsia, assuming no other-cause delivery. This distribution is
obtained using Bayes’ theorem to combine a prior distribution of g, given Mat-CHs, with a likelihood
function for g from biomarker MoM values. For a given posterior distribution, risks of pre-eclampsia
occurring in a particular gestational age interval are obtained by integrating the posterior distribution
over the interval. The model used in this appendix is from N Engl J Med, Rolnik DL, Wright D, Poon LC,
O’Gorman N, Syngelaki A, de Paco Matallana C, et al., Aspirin versus placebo in pregnancies at high risk
for preterm preeclampsia, 377, 613–22. Copyright © 2017 Massachusetts Medical Society. Reprinted
with permission from Massachusetts Medical Society.7
The prior model
The prior model assumes that g has a Gaussian distribution with mean µg and standard deviation σg.
The mean µg is obtained from the regression model with the parameters given in Table 22.
TABLE 22 History model regression coefficients
Term Coefficient
Constant 54.3637
Age (years) (–35 if age > 35; 0 if age < 35) –0.206886
Height (cm): 164 0.11711
Afro-Caribbean racial origin –2.6786
South Asian racial origin –1.129
Chronic hypertension –7.2897
Systemic lupus erythematosus or antiphospolipid syndrome –3.0519
Conception by in vitro fertilisation –1.6327
Parous with previous pre-eclampsia –8.1667
Parous with previous pre-eclampsia: [previous GA (week)–24]2 0.0271988
Parous with no previous pre-eclampsia: intercept –4.335
Parous with no previous pre-eclampsia: interval (years)–1 –4.15137651
Parous with no previous pre-eclampsia: interval (years)–0.5 9.21473572
Parous with no previous pre-eclampsia: [previous GA (week)–24]2 0.01549673
(Weight in kg – 69) × (not CH) –0.0694096
(Family history of pre-eclampsia) × (not CH) –1.7154
[Diabetes mellitus (type 1 or 2)] × (not CH) –3.3899
Scale 6.8833
Age lower limit 12
Age upper limit 55
continued
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Likelihood
The likelihood is a multivariate Gaussian density for the distribution of biomarker log10 MoM values
conditional on g. The elements of the mean vector (µx) of this distribution are given by the broken
stick model:
β0 + β1g if g<−β0 /β1, (3)
0 else.
The estimated regression parameters and biomarker likelihood covariance matrix are given in Tables 23
and 24, respectively.
TABLE 22 History model regression coefficients (continued )
Term Coefficient
Weight lower limit 34
Weight upper limit 190
Height lower limit 127
Height upper limit 198
Interval lower limit 0.25
Interval upper limit 15
Previous GA lower limit 24
Previous GA upper limit 42
CH, chronic hypertension; GA, gestational age.






TABLE 24 Biomarker likelihood covariance matrix
Term m1 u1 plgf1 p1
m1 0.001413964 –0.000272567 –0.000190680 –0.000030300
u1 –0.000272567 0.016309062 –0.003453917 –0.004901669
plgf1 –0.00019068 –0.003453917 0.031472254 0.013331676
p1 –0.000030300 –0.004901669 0.013331676 0.056500355
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Posterior probability density
The posterior probability density p(g), up to a normalising constant, is calculated by multiplying the
likelihood by the prior:
p(g) = dmvnorm(x, µx,Σx) × dnorm(g, µg , σ2g ). (4)
In Equation 4, dmvnorm is the multivariate Gaussian density for x, with mean µx and covariance matrix Σx.
dnorm is the univariate Gaussian density for g, with mean µg and standard deviation σg according to the
history model.
Posterior risks
The risk of pre-eclampsia requiring delivery before gestation G (weeks), assuming no other-cause







where g* =max(24, Current gestation).
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Appendix 2 WinBUGS model for
data imputation
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centre: vector of 16,747 centre labels.
event: vector of 16,747 observed pre-eclampsia events (0 = no event; 1 = pre-eclampsia).
aspirin: vector of 16,747 aspirin indicators (0 = no aspirin; 1 = aspirin).
nice: vector of 16,747 indicators (0 =NICE negative, 1 =NICE positive).
risk: vector of 16,747 indicators (0 = risk negative, 1 = risk positive).
5000 Markov chain Monte Carlo iterations were carried out to ensure convergence and checked
visually using parameter trace plots.
A further 1000 iterations were carried out and values of the counts s1, s2, s3 and s4 were recorded
for observation 100, 200, . . . , 1000, providing 10 imputed data sets. The observed event counts and
imputed counts, assuming a relative risk reduction with aspirin of 0.3, allowing for the effects of aspirin
are shown in Table 25. It is notable that the number of events imputed in the NICE positive and risk
negative cell exceeds that in the NICE negative and risk positive group. The reflects the different numbers
treated by aspirin in the two groups. This reduces the effect size (see Figures 8 and 9).
Estimates and their standard errors of the difference in DRs were computed for each of the imputed
data sets. These were then pooled using the formula (3.1.2) of Rubin.66
TABLE 25 Observed event counts and imputed counts assuming a relative risks reduction with aspirin of 0.3
Data set
NICE, risk
Positive, positive Positive, negative Negative, positive Negative, negative
Observed events 119 25 83 119
Imputation 5100 125 30 83 125
Imputation 5200 123 30 83 123
Imputation 5300 124 26 83 124
Imputation 5400 121 30 83 121
Imputation 5500 122 26 85 122
Imputation 5600 124 31 83 124
Imputation 5700 127 32 83 127
Imputation 5800 125 30 83 125
Imputation 5900 124 27 84 124
Imputation 6000 126 27 83 126
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Appendix 3 Sensitivity analysis for the
effect of aspirin
All pre-eclampsia
Difference in DRs (i.e. mini-combined test –NICE method) of pre-eclampsia at any gestational age for
a fixed SPR of 10.3% defined by NICE (Figure 20).
–5 0 5 10
Difference in DR (%)
15 20
10.9% (6.7% to 15.1%)
11% (6.8% to 15.2%)
11.9% (7.7% to 16%)
11% (6.8% to 15.2%)
12.2% (8.1% to 16.3%)
10.7% (6.5% to 14.9%)
10.5% (6.2% to 14.7%)
10.8% (6.7% to 15%)
11.8% (7.7% to 15.9%)
11.6% (7.5% to 15.7%)
Pooled: 11.2% (6.9% to 15.6%)
Without imputation: 12.3% (8.1% to 16.4%)
(a)
–5 0 5 10
Difference in DR (%)
15 20
9.6% (5.4% to 13.8%)
9.9% (5.7% to 14.1%)
11.3% (7.2% to 15.4%)
10.4% (6.2% to 14.6%)
11.7% (7.5% to 15.8%)
10.4% (6.2% to 14.6%)
9.4% (5.2% to 13.7%)
10.8% (6.7% to 14.9%)
11.7% (7.5% to 15.8%)
10.8% (6.7% to 15%)
Pooled: 10.6% (6.1% to 15.1%)
Without imputation: 12.3% (8.1% to 16.4%)
(b)
FIGURE 20 Difference in DRs for pre-eclampsia with delivery at any gestational age [mini-combined test (i.e. Mat-CHs,
MAP+ PAPP-A) vs. the NICE method] with a relative risk reduction from aspirin of (a) 30%; (b) 50%; and (c) 100%. (continued )
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Pre-eclampsia with delivery before 37 weeks
Difference in DRs (i.e. mini-combined test vs. NICE method) of preterm pre-eclampsia (< 37 weeks’
gestation) for a fixed SPR of 10.3% defined by NICE (Figure 21).
–5 0 5 10
Difference in DR (%)
15 20
7.2% (3% to 11.4%)
8.9% (4.7% to 13.2%)
10% (5.9% to 14.1%)
8.5% (4.4% to 12.7%)
7.3% (3% to 11.6%)
8.2% (4% to 12.4%)
9.5% (5.4% to 13.7%)
7.5% (3.3% to 11.7%)
8.6% (4.4% to 12.8%)
9.2% (5% to 13.3%)
Pooled: 8.5% (3.9% to 13.1%)
Without imputation: 12.3% (8.1% to 16.4%)
(c)
FIGURE 20 Difference in DRs for pre-eclampsia with delivery at any gestational age [mini-combined test (i.e. Mat-CHs,
MAP+ PAPP-A) vs. the NICE method] with a relative risk reduction from aspirin of (a) 30%; (b) 50%; and (c) 100%.
–5 0 5 10
Difference in DR (%)
15 20
8.5% (0.4% to 16.6%)
9.3% (1.2% to 17.5%)
8.4% (0.4% to 16.4%)
8.4% (0.4% to 16.5%)
12.7% (4.8% to 20.6%)
8.7% (0.4% to 17%)
7% (–1.1% to 15%)
9.1% (1.2% to 17%)
12% (4.2% to 19.8%)
10.1% (2% to 18.1%)
Pooled: 9.4% (0.6% to 18.2%)
Without imputation: 12.7% (4.7% to 20.7%)
(a)
FIGURE 21 Difference in DRs (Mat-CHs +MAP + PAPP-A vs. the NICE method) with a relative risk reduction from
aspirin of (a) 60%; (b) 80%; and (c) 100%. (continued )
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
–5 0 5 10
Difference in DR (%)
15 20
9% (1% to 17%)
8.3% (0.4% to 16.3%)
9.7% (1.9% to 17.4%)
9.2% (1.2% to 17.2%)
8.2% (0.2% to 16.2%)
8.6% (0.4% to 16.8%)
10.1% (2.2% to 17.9%)
7.8% (–0.6% to 16.1%)
9.9% (1.8% to 18.1%)
7.5% (–0.5% to 15.4%)
Pooled: 8.8% (0.6% to 17.1%)
Without imputation: 12.7% (4.7% to 20.7%)
(b)
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Difference in DR (%)
15 20
8.7% (0.9% to 16.5%)
6.2% (–1.8% to 14.3%)
5% (–3.3% to 13.2%)
7.5% (–0.4% to 15.4%)
4.8% (–3.1% to 12.7%)
6.2% (–2% to 14.4%)
7.8% (0.2% to 15.5%)
4.8% (–3.1% to 12.7%)
3.6% (–4.6% to 11.8%)
7% (–1.1% to 15.1%)
Pooled: 6.2% (–2.5% to 14.8%)
Without imputation: 12.7% (4.7% to 20.7%)
(c)
FIGURE 21 Difference in DRs (Mat-CHs +MAP + PAPP-A vs. the NICE method) with a relative risk reduction from
aspirin of (a) 60%; (b) 80%; and (c) 100%.
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Pre-eclampsia with delivery before 37 weeks
Difference in DRs (i.e. Mat-CHs, MAP and PLGF vs. the NICE method) of preterm pre-eclampsia
(< 37 weeks’ gestation) for a fixed SPR of 10.3% defined by NICE (Figure 22).
0 10 20
Difference in DR (%)
30 40
22.2% (13.1% to 31.3%)
22.7% (13.4% to 31.9%)
21.9% (12.9% to 30.9%)
22.7% (13.8% to 31.6%)
26.7% (18.1% to 35.3%)
24.2% (15.1% to 33.2%)
19.6% (10.4% to 28.8%)
22.1% (13% to 31.1%)
26.7% (18.1% to 35.3%)
23.5% (14.3% to 32.7%)
Pooled: 23.2% (13.2% to 33.3%)
Without imputation: 28.2% (19.4% to 37%)
(a)
0 10 20
Difference in DR (%)
30 40
22.4% (13.6% to 31.2%)
20.5% (11.3% to 29.7%)
21.9% (12.9% to 30.9%)
22.4% (13.2% to 31.5%)
22% (13.4% to 30.7%)
22.5% (13.3% to 31.7%)
22.6% (13.9% to 31.3%)
20.1% (10.7% to 29.5%)
24.5% (15.5% to 33.5%)
18.6% (9.3% to 27.9%)
Pooled: 21.8% (12.1% to 31.4%)
Without imputation: 28.2% (19.4% to 37%)
(b)
FIGURE 22 Difference in DRs (Mat-CHs +MAP + PLGF vs. the NICE method) with a relative risk reduction from aspirin
of (a) 60%; (b) 80%; and (c) 100%. (continued )
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Pre-eclampsia with delivery before 37 weeks
Difference in DRs (i.e. Mat-CHs, MAP, UTA-PI and PLGF vs. the NICE method) of preterm pre-eclampsia
(< 37 weeks’ gestation) for a fixed SPR of 10.3% defined by NICE (Figure 23).
0 10 20
Difference in DR (%)
30 40
20.5% (11.7% to 29.3%)
20% (11% to 29%)
19.9% (11% to 28.8%)
22.5% (14% to 31%)
18.6% (9.8% to 27.3%)
19.9% (10.8% to 29%)
19.3% (10.5% to 28.1%)
17.4% (8.4% to 26.3%)
17% (7.8% to 26.1%)
19.7% (10.5% to 29%)
Pooled: 19.5% (10% to 29%)
Without imputation: 28.2% (19.4% to 37%)
(c)
FIGURE 22 Difference in DRs (Mat-CHs +MAP + PLGF vs. the NICE method) with a relative risk reduction from aspirin
of (a) 60%; (b) 80%; and (c) 100%.
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34.2% (25.4% to 43%)
35.7% (27.1% to 44.3%)
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31.6% (22.5% to 40.8%)
33.8% (24.7% to 42.8%)
40% (31.7% to 48.3%)
35.6% (26.4% to 44.7%)
Pooled: 35.5% (25.2% to 45.8%)
Without imputation: 41.5% (33.2% to 49.9%)
(a)
FIGURE 23 Difference in DRs (Mat-CHs +MAP + PLGF vs. the NICE method) with a relative risk reduction from aspirin
of (a) 60%; (b) 80%; and (c) 100%. (continued )
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35.8% (26.9% to 44.6%)
33.3% (24.5% to 42.2%)
32.5% (23.1% to 41.8%)
37.1% (28.4% to 45.8%)
31.7% (22.7% to 40.7%)
Pooled: 33.9% (24.3% to 43.5%)
Without imputation: 41.5% (33.2% to 49.9%)
(b)
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31.7% (22.8% to 40.5%)
31.2% (22.2% to 40.3%)
29.8% (20.6% to 39.1%)
33.8% (25.3% to 42.2%)
28.1% (19.1% to 37.2%)
29.8% (20.4% to 39.2%)
31.3% (22.7% to 40%)
28.1% (19.1% to 37.2%)
28.5% (19.3% to 37.7%)
30.6% (21.1% to 40%)
Pooled: 30.3% (20.5% to 40.1%)
Without imputation: 41.5% (33.2% to 49.9%)
(c)
FIGURE 23 Difference in DRs (Mat-CHs +MAP + PLGF vs. the NICE method) with a relative risk reduction from aspirin
of (a) 60%; (b) 80%; and (c) 100%.
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Appendix 4 Performance of screening for
pre-eclampsia by the competing risk model
In the receiver operating characteristic plots (Figures 24–32) the dark blue line is for predictionof pre-eclampsia at < 32 weeks’ gestation, the light blue line for pre-eclampsia at < 37 weeks’
gestation, the grey line for pre-eclampsia at ≥ 37 weeks’ gestation and the orange line for all






































FIGURE 25 Performance of screening for pre-eclampsia with Mat-CHs and MAP.
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FIGURE 28 Performance of screening for pre-eclampsia with Mat-CHs and PAPP-A.
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FIGURE 31 Performance of screening for pre-eclampsia with Mat-CHs, MAP and PLGF.
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FIGURE 32 Performance of screening for pre-eclampsia with Mat-CHs, MAP, PLGF and UTA-PI.
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Appendix 5 The SPREE study calibration
F igures 33–86 show the estimated incidence against risk of pre-eclampsia in bins defined accordingto risk. Estimates and 95% CIs are shown for the incidence within each bin. The diagonal light blue
line is the line of perfect agreement. The overall mean risk is shown by the vertical dashed line and
the overall incidence by the horizontal dashed line. The histograms show risks grouped by risk in those
with pre-eclampsia before the specified gestation (orange) and those without pre-eclampsia before the
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FIGURE 34 Adjusted calibration plot for Mat-CHs in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 36 Adjusted calibration plot for Mat-CHs in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 38 Adjusted calibration plot for Mat-CHs in predicting all pre-eclampsia.
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FIGURE 40 Adjusted calibration plot for Mat-CHs and MAP in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 42 Adjusted calibration plot for Mat-CHs and MAP in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 44 Adjusted calibration plot for Mat-CHs and MAP in predicting all pre-eclampsia.
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FIGURE 46 Adjusted calibration plot for Mat-CHs and UTA-PI in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 48 Adjusted calibration plot for Mat-CHs and UTA-PI in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 50 Adjusted calibration plot for Mat-CHs and UTA-PI in predicting all pre-eclampsia.
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FIGURE 52 Adjusted calibration plot for Mat-CHs and PLGF in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 54 Adjusted calibration plot for Mat-CHs and PLGF in predicting pre-eclampsia at < 37 weeks’ gestation.
DOI: 10.3310/eme07080 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 8
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Poon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,





























–0.072 (–0.172 to 0.028)




0.001 0.002 0.005 0.01 0.02
Risk of pre-eclampsia at < 41 weeks’ gestation


















































0.001 0.002 0.005 0.01 0.02
Risk of pre-eclampsia at < 41 weeks’ gestation

















FIGURE 56 Adjusted calibration plot for Mat-CHs and PLGF in predicting all pre-eclampsia.
APPENDIX 5








































0.364 (0.103 to 0.624)




0.001 0.002 0.005 0.01 0.02
Risk of pre-eclampsia at < 34 weeks’ gestation
























































0.001 0.002 0.005 0.01 0.02
Risk of pre-eclampsia at < 34 weeks’ gestation

















FIGURE 58 Adjusted calibration plot for Mat-CHs and PAPP-A in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 60 Adjusted calibration plot for Mat-CHs and PAPP-A in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 62 Adjusted calibration plot for Mat-CHs and PAPP-A in predicting all pre-eclampsia.
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FIGURE 64 Adjusted calibration plot for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 66 Adjusted calibration plot for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 68 Adjusted calibration plot for Mat-CHs, MAP and UTA-PI in predicting all pre-eclampsia.
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FIGURE 70 Adjusted calibration plot for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 72 Adjusted calibration plot for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 74 Adjusted calibration plot for Mat-CHs, MAP and PAPP-A in predicting all pre-eclampsia.
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FIGURE 76 Adjusted calibration plot for Mat-CHs, MAP and PLGF in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 78 Adjusted calibration plot for Mat-CHs, MAP and PLGF in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 80 Adjusted calibration plot for Mat-CHs, MAP and PLGF in predicting all pre-eclampsia.
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FIGURE 81 Calibration plot for Mat-CHs, MAP, PLGF and UTA-PI in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 83 Calibration plot for Mat-CHs, MAP, PLGF and UTA-PI in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 85 Calibration plot for Mat-CHs, MAP, PLGF and UTA-PI in predicting all pre-eclampsia.
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Figures 87–140 show the estimated incidence/mean risk within each bin.
Calibration plots are shown for incidence without and with adjustment for censoring. For the plots
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FIGURE 87 The estimated incidence/mean risk within each bin forMat-CHs in predicting pre-eclampsia at< 34weeks’ gestation.
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FIGURE 89 The estimated incidence/mean risk within each bin forMat-CHs in predicting pre-eclampsia at< 37weeks’ gestation.
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FIGURE 91 The estimated incidence/mean risk within each bin for Mat-CHs in predicting all pre-eclampsia.
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FIGURE 94 The estimated incidence/mean risk within each bin for Mat-CHs and MAP in predicting pre-eclampsia at
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FIGURE 93 The estimated incidence/mean risk within each bin for Mat-CHs and MAP in predicting pre-eclampsia at
< 34 weeks’ gestation.
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FIGURE 96 The estimated incidence/mean risk within each bin for Mat-CHs and MAP in predicting pre-eclampsia at
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FIGURE 95 The estimated incidence/mean risk within each bin for Mat-CHs and MAP in predicting pre-eclampsia at
< 37 weeks’ gestation.
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FIGURE 97 The estimated incidence/mean risk within each bin for Mat-CHs and MAP in predicting all pre-eclampsia.
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FIGURE 100 The estimated incidence/mean risk within each bin for Mat-CHs and UTA-PI in predicting pre-eclampsia at
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FIGURE 99 The estimated incidence/mean risk within each bin for Mat-CHs and UTA-PI in predicting pre-eclampsia at
< 34 weeks’ gestation.
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FIGURE 102 The estimated incidence/mean risk within each bin for Mat-CHs and UTA-PI in predicting pre-eclampsia at
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FIGURE 101 The estimated incidence/mean risk within each bin for Mat-CHs and UTA-PI in predicting pre-eclampsia at
< 37 weeks’ gestation.
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FIGURE 103 The estimated incidence/mean risk within each bin for Mat-CHs and UTA-PI in predicting all pre-eclampsia.
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FIGURE 106 The estimated incidence/mean risk within each bin for Mat-CHs and PLGF in predicting pre-eclampsia at
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FIGURE 105 The estimated incidence/mean risk within each bin for Mat-CHs and PLGF in predicting pre-eclampsia at
< 34 weeks’ gestation.
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FIGURE 108 The estimated incidence/mean risk within each bin for Mat-CHs and PLGF in predicting pre-eclampsia at
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FIGURE 107 The estimated incidence/mean risk within each bin for Mat-CHs and PLGF in predicting pre-eclampsia at
< 37 weeks’ gestation.
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FIGURE 109 The estimated incidence/mean risk within each bin for Mat-CHs and PLGF in predicting all pre-eclampsia.
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FIGURE 112 The estimated incidence/mean risk within each bin for Mat-CHs and PAPP-A in predicting pre-eclampsia at
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FIGURE 111 The estimated incidence/mean risk within each bin for Mat-CHs and PAPP-A in predicting pre-eclampsia at
< 34 weeks’ gestation.
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FIGURE 114 The estimated incidence/mean risk within each bin for Mat-CHs and PAPP-A in predicting pre-eclampsia at
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FIGURE 113 The estimated incidence/mean risk within each bin for Mat-CHs and PAPP-A in predicting pre-eclampsia at
< 37 weeks’ gestation.
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FIGURE 115 The estimated incidence/mean risk within each bin for Mat-CHs and PAPP-A in predicting all pre-eclampsia.
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FIGURE 118 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia
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FIGURE 117 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia
at < 34 weeks’ gestation.
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FIGURE 120 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia
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FIGURE 119 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and UTA-PI in predicting pre-eclampsia
at < 37 weeks’ gestation.
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FIGURE 121 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and UTA-PI in predicting all
pre-eclampsia.
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FIGURE 124 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia
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FIGURE 123 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia
at < 34 weeks’ gestation.
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FIGURE 126 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia
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FIGURE 125 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PAPP-A in predicting pre-eclampsia
at < 37 weeks’ gestation.
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FIGURE 127 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PAPP-A in predicting all
pre-eclampsia.
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FIGURE 130 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PLGF in predicting pre-eclampsia
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FIGURE 129 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PLGF in predicting pre-eclampsia
at < 34 weeks’ gestation.
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FIGURE 132 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PLGF in predicting pre-eclampsia
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FIGURE 131 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PLGF in predicting pre-eclampsia
at < 37 weeks’ gestation.
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FIGURE 133 The estimated incidence/mean risk within each bin for Mat-CHs, MAP and PLGF in predicting all pre-eclampsia.
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FIGURE 136 The estimated incidence/mean risk within each bin for Mat-CHs, MAP, PLGF and UTA-PI in predicting
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FIGURE 135 The estimated incidence/mean risk within each bin for Mat-CHs, MAP, PLGF and UTA-PI in predicting
pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 138 The estimated incidence/mean risk within each bin for Mat-CHs, MAP, PLGF and UTA-PI in predicting
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FIGURE 137 The estimated incidence/mean risk within each bin for Mat-CHs, MAP, PLGF and UTA-PI in predicting
pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 139 The estimated incidence/mean risk within each bin for Mat-CHs, MAP, PLGF and UTA-PI in predicting all
pre-eclampsia.
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Appendix 6 The SPREE study decision curves
In Figures 141–152, the dark blue lines are for prediction of pre-eclampsia before 34 weeks’gestation, before 37 weeks’ gestation and at any gestational age using the competing risk with
different combinations of markers. The light blue curve is the decision curve for the policy of screening
everyone positive. The orange line is the decision curve for screening everyone negative. In general,
the decision curves for the combined test are superior to the policies of screening everyone positive
or screening everyone negative for the range of threshold probabilities that would seem reasonable.
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FIGURE 141 Decision curve for Mat-CHs in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 142 Decision curve for Mat-CHs in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 143 Decision curve for Mat-CHs in predicting all pre-eclampsia.
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FIGURE 144 Decision curve for Mat-CHs and MAP in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 145 Decision curve for Mat-CHs and MAP in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 146 Decision curve for Mat-CHs and MAP in predicting all pre-eclampsia.
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FIGURE 147 Decision curve for Mat-CHs and UTA-PI in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 148 Decision curve for Mat-CHs and UTA-PI in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 149 Decision curve for Mat-CHs and UTA-PI in predicting all pre-eclampsia.
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FIGURE 150 Decision curve for Mat-CHs, MAP, PLGF and UTA-PI in predicting pre-eclampsia at < 34 weeks’ gestation.
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FIGURE 151 Decision curve for Mat-CHs, MAP, PLGF and UTA-PI in predicting pre-eclampsia at < 37 weeks’ gestation.
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FIGURE 152 Decision curve for Mat-CHs, MAP, PLGF and UTA-PI in predicting all pre-eclampsia.
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Appendix 7 Performance of screening for
preterm pre-eclampsia by the competing
risk model in three data sets
In Figures 153–161, the orange line is for the population used for development of the algorithm(AJOG),19 the dark blue line is for the SPREE study,50 the light blue line is for ASPRE SQS47 and the






































FIGURE 153 Performance of screening for preterm pre-eclampsia by Mat-CHs.
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FIGURE 157 Performance of screening for preterm pre-eclampsia by Mat-CHs and PAPP-A.
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FIGURE 160 Performance of screening for preterm pre-eclampsia by Mat-CHs, MAP and PLGF.
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FIGURE 161 Performance of screening for preterm pre-eclampsia by Mat-CHs, MAP, PLGF and UTA-PI.
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